var title_f7_48_7936="Impacted common bile duct stone";
var content_f7_48_7936=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F60965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F60965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Impacted common bile duct stone",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 403px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Impacted common bile duct stone (arrow). Characteristic smooth, concave intraluminal filling defect.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Eisenberg, RL. An Atlas of Differential Diagnosis, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_48_7936=[""].join("\n");
var outline_f7_48_7936=null;
var title_f7_48_7937="Calculator: QT Interval Correction (EKG)";
var content_f7_48_7937=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"QTIntervalCorrection_form\" name=\"QTIntervalCorrection_form\" onkeydown=\"clrResults();\" onkeyup=\"QTIntervalCorrection_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: QT Interval Correction (EKG)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         RRInterval = 60 / HeartRate",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         QTICorrected = QTInterval / sqr(RRInterval)",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"      <tr>",
"       <td align=\"right\" width=\"50%\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Input:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             QT Interval",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"QT_Interval_param\" onblur=\"QTIntervalCorrection_fx(); minMaxCheck();\" onchange=\"QTIntervalCorrection_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"QT_Interval_unit\" onchange=\"QTIntervalCorrection_fx();\" style=\"width:105px;\">",
"             <option value=\"0.001|0|msec\">",
"              msec",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|sec\">",
"              sec",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Heart Rate",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Heart_Rate_param\" onblur=\"QTIntervalCorrection_fx(); minMaxCheck();\" onchange=\"QTIntervalCorrection_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Heart_Rate_unit\" onchange=\"QTIntervalCorrection_fx();\" style=\"width:105px;\">",
"             <option selected=\"selected\" value=\"1|0|bpm\">",
"              bpm",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Results:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             RR Interval",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"RR_Interval_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td valign=\"top\">",
"            <span class=\"medCalcFontOne\">",
"             <select class=\"medCalcFontSelect\" name=\"RR_Interval_unit\" onchange=\"QTIntervalCorrection_fx();\" style=\"width:105px;\">",
"              <option value=\"0.001|0|msec\">",
"               msec",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|sec\">",
"               sec",
"              </option>",
"             </select>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             QTI Corrected",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"QTI_Corrected_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td valign=\"top\">",
"            <span class=\"medCalcFontOne\">",
"             <select class=\"medCalcFontSelect\" name=\"QTI_Corrected_unit\" onchange=\"QTIntervalCorrection_fx();\" style=\"width:105px;\">",
"              <option value=\"0.001|0|msec\">",
"               msec",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|sec\">",
"               sec",
"              </option>",
"             </select>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"3\">",
"            &nbsp;",
"            <br/>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"center\" colspan=\"3\">",
"            <span class=\"medCalcFontOneBold\">",
"             Decimal Precision:",
"            </span>",
"            <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"QTIntervalCorrection_fx();\">",
"             <option>",
"              0",
"             </option>",
"             <option>",
"              1",
"             </option>",
"             <option selected=\"selected\">",
"              2",
"             </option>",
"             <option>",
"              3",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontRef\">",
"     <b>",
"      References",
"     </b>",
"    </span>",
"    <ol>",
"     <li>",
"      <span class=\"medCalcFontRef\">",
"       Bazett HC. An analysis of the time relationships of electrocardiograms.",
"       <i>",
"        Heart",
"       </i>",
"       . 1920;7:355-70.",
"      </span>",
"     </li>",
"    </ol>",
"   </form>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_48_7937=[" /* <![CDATA[ */",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function QTIntervalCorrection_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.QTIntervalCorrection_form){",
"",
"",
"doCalc = true;",
"if (QT_Interval_param.value.indexOf(',') >= 0){ QT_Interval_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(QT_Interval_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = QT_Interval_unit.options[QT_Interval_unit.selectedIndex].value.split('|');",
"QT_Interval = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Heart_Rate_param.value.indexOf(',') >= 0){ Heart_Rate_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Heart_Rate_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Heart_Rate_unit.options[Heart_Rate_unit.selectedIndex].value.split('|');",
"Heart_Rate = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"RR_Interval =  60 / Heart_Rate;",
"",
"unit_parts = RR_Interval_unit.options[RR_Interval_unit.selectedIndex].value.split('|');",
"if (doCalc) RR_Interval_param.value = fixDP((RR_Interval - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"QTI_Corrected =  QT_Interval / sqr(RR_Interval);",
"",
"unit_parts = QTI_Corrected_unit.options[QTI_Corrected_unit.selectedIndex].value.split('|');",
"if (doCalc) QTI_Corrected_param.value = fixDP((QTI_Corrected - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.QTIntervalCorrection_form){",
"",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.QTIntervalCorrection_form){",
"",
"RR_Interval_param.value = '';",
"QTI_Corrected_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"/* ]]> */"].join("\n");
var outline_f7_48_7937=null;
var title_f7_48_7938="Abdominal pregnancy";
var content_f7_48_7938=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Abdominal pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 274px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transabdominal ultrasonography of an abdominal pregnancy at 15 weeks of gestation. Note the lack of myometrium around the gestational sac.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_48_7938=[""].join("\n");
var outline_f7_48_7938=null;
var title_f7_48_7939="Raxibacumab: Patient drug information";
var content_f7_48_7939=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Raxibacumab: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32755?source=see_link\">",
"     see \"Raxibacumab: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F16254969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4179788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to prevent or treat anthrax.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F16254499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4179786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to raxibacumab or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F16254500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F16254972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4179789",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pain in arms or legs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F16254501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F16254971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694654",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Diphenhydramine may be given before this drug to lower itching.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F16254502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 88575 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-23F828356C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_48_7939=[""].join("\n");
var outline_f7_48_7939=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16254969\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16254499\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16254500\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16254972\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16254501\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16254971\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16254502\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32755?source=related_link\">",
"      Raxibacumab: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_48_7940="Eumycetoma after treatment";
var content_f7_48_7940=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mycetoma after 2 years of treatment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    T1-weighted MRI with intravenous gadolinium and fat suppression of a pedal mycetoma after 2 years of treatment. Bone cavities are clearly delineated by areas of higher signal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beatriz Bustamante, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_48_7940=[""].join("\n");
var outline_f7_48_7940=null;
var title_f7_48_7941="Algorithm for treatment of nausea and vomiting of pregnancy";
var content_f7_48_7941=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 631px\">",
"   <div class=\"ttl\">",
"    Management algorithm for prevention and treatment of nausea and vomiting of pregnancy (NVP)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 611px; height: 804px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <ol>",
"     <li>",
"      Start patients with mild cases of NVP on non-pharmacologic interventions",
"      <ul>",
"       <li>",
"        Dietary changes first",
"       </li>",
"       <li>",
"        Lifestyle modifications (could be disruptive to work day, so reserve for when feasible)",
"       </li>",
"      </ul>",
"     </li>",
"     <li>",
"      If diet and lifestyle changes alone are not working consider complementary and alternative medicine interventions",
"      <ul>",
"       <li>",
"        Acupressure (",
"        <strong>",
"         Note:",
"        </strong>",
"        Should be removed when sleeping at night)",
"       </li>",
"       <li>",
"        Ginger supplement or ginger tea",
"       </li>",
"      </ul>",
"     </li>",
"     <li>",
"      Patients with persistent NVP or moderate NVP to HG, initiate the non-pharmacologic interventions above plus pharmacotherapy.",
"      <strong>",
"       Note:",
"      </strong>",
"      Use clinical judgment, if dehydration is suspected or inability to eat/drink for greater than 12 hours, then go directly to IV fluid replacement + ondansetron 4 to 8 mg IV q 8 hours. Otherwise follow a systematic approach, adding/substituting a new agent as indicated in the flow chart.",
"      <ul>",
"       <li>",
"        We prefer to treat outpatients with PO drugs, but IV drugs are also often feasible with home healthcare",
"       </li>",
"       <li>",
"        If the patient is not achieving control of NVP with one drug, then proceed to the next step in the algorithm",
"       </li>",
"       <li>",
"        We individualize regimens based upon the patient's side effects and response (control of NVP)",
"       </li>",
"       <li>",
"        Pregnant women with NVP/HG may go on and off drug treatment and may switch back and forth among several different drugs and among oral, IM, PR, and IV routes of administration. We individualize therapy depending on how the patient is responding to her current treatment.",
"       </li>",
"      </ul>",
"     </li>",
"    </ol>",
"    <div class=\"footnotes\">",
"     NVP: nausea and vomiting of pregnancy; HG: hyperemesis gravidarum; OTC: over the counter; P6: pericardium 6; po: orally; IV: intravenously; PR: per rectum; IM; intramuscularly; Q: every; h: hours; min: minutes; PRN: as needed; BID: two times per day; TID: three times per day; QID: four times per day.",
"     <br/>",
"     * GERD: gastroesophageal reflux disease, which can be treated with H2 receptor antagonists (eg, ranitidine and cimetidine).",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_48_7941=[""].join("\n");
var outline_f7_48_7941=null;
var title_f7_48_7942="Strategies other than treatment of stenosis to prevent thrombosis of hemodialysis vascular access grafts";
var content_f7_48_7942=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Strategies other than treatment of stenosis to prevent thrombosis of hemodialysis vascular access grafts",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/48/7942/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/48/7942/contributors\">",
"     Michael Allon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/48/7942/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/48/7942/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/48/7942/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/48/7942/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/48/7942/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodialysis requires access to blood vessels capable of providing rapid extracorporeal blood flow. These requirements are currently best met by both primary arteriovenous (AV) fistulas and synthetic grafts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23816?source=see_link\">",
"     \"Arteriovenous fistulas and grafts for chronic hemodialysis access\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Access failure is primary due to irreversible thrombosis. Greater than 90 percent of thrombosed grafts have a stenotic lesion, which is commonly treated with percutaneous transluminal angioplasty",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgery. However, mechanical approaches that rely upon preemptive angioplasty to treat stenosis to help graft failure are associated with disappointing results. Thus, alternative strategies to prevent graft thrombosis may be beneficial.",
"   </p>",
"   <p>",
"    Strategies to prevent thrombosis of hemodialysis AV grafts other than treatment of the stenosis are presented in this topic review. Management of stenosis of hemodialysis access is presented separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular access stenosis of a hemodialysis AV graft is initiated by endothelial cell injury, which leads to the upregulation of adhesion molecules on the endothelial cell surface. Subsequent leukocyte adherence to damaged and activated endothelium causes the release of chemotactic and mitogenic factors for vascular smooth muscle cells, thereby enhancing smooth muscle cell migration and proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7942/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional factors that contribute to the neointimal proliferation and fibromuscular hyperplasia include shear stress generated by the turbulent blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7942/abstract/4,5\">",
"     4,5",
"    </a>",
"    ], and the mismatch in elastic properties around the anastomosis leading to excessive mechanical stretch [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7942/abstract/6\">",
"     6",
"    </a>",
"    ]. Activated platelets and inflammatory cells also secrete oxidants and other toxins that directly injure the vessel wall [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7942/abstract/7\">",
"     7",
"    </a>",
"    ]. Finally, angioplasty of stenotic lesions exacerbates neointimal hyperplasia, resulting in accelerated restenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7942/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although unproven, measures aimed to prevent neointimal hyperplasia as well as other pharmacologic agents that address some of the elements underlying vascular stenosis may help prevent stenosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANTIPLATELET AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiplatelet agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    and low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    with or without sulfinpyrazone, aspirin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , have been employed in an attempt to reduce graft thrombosis rates [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7942/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. Results have been conflicting, due in part to the use of variable treatment regimens and enrollment of different patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest study, 649 patients with a new arteriovenous graft were randomly assigned to extended release",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      (200 mg twice daily) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (25 mg twice daily) or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?7/48/7942/abstract/12\">",
"       12",
"      </a>",
"      ]. Active therapy was associated with a significant, but modest, increase in the incidence of primary unassisted patency (no thrombosis or intervention) at one year (28 versus 23 percent). Both groups had a similar incidence of adverse events (particularly bleeding), graft failure, and death. The combination of dipyridamole plus aspirin may have been associated with an incidence of bleeding that was lower than anticipated because of the exclusion of patients with an increased bleeding risk and the short duration of use of the drugs.",
"      <br/>",
"      <br/>",
"      Forty three percent of patients were taking aspirin prior to trial entry and were allowed to continue for the duration of the trial. In a secondary analysis, at one year, aspirin use compared with no aspirin use at baseline (ie, prior to trial entry) was associated with a non-statistically significant increase in graft patency (30 versus 23 percent, respectively), and after adjusting for multiple covariates, a 17 percent lower rate of loss of patency (adjusted hazard ratio 0.83, 95% CI 0.68-1.01) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/48/7942/abstract/13\">",
"       13",
"      </a>",
"      ]. There was no difference between groups in the overall rate of bleeding, death, hospitalization or vascular access events. These data suggest that aspirin alone may safely prevent loss of graft patency, although as noted above, patients at high risk for bleeding were excluded from the trial.",
"     </li>",
"     <li>",
"      A single-center randomized clinical trial compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      (75 mg, three",
"      <span class=\"nowrap\">",
"       times/day)",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (325",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      for the prevention of thrombosis in expanded polytetrafluoroethylene (PTFE) grafts [",
"      <a class=\"abstract\" href=\"UTD.htm?7/48/7942/abstract/10\">",
"       10",
"      </a>",
"      ]. Neither therapy appeared to be effective in patients with previous thrombosis, as the recurrence rate was 78 percent within 18 months. In 84 patients with new grafts, however, the rate of thrombosis was substantially reduced by dipyridamole (relative risk 0.35 versus placebo). Dipyridamole lowered graft thrombosis whether it was administered alone or in conjunction with aspirin. However, the magnitude of the benefit of aspirin + dipyridamole was considerably smaller in the previously cited study.",
"     </li>",
"     <li>",
"      A well-designed multicenter study with 200 patients evaluated the effectiveness of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      versus placebo in preventing graft thrombosis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/48/7942/abstract/11\">",
"       11",
"      </a>",
"      ]. The study was stopped because of a doubled risk of bleeding among those receiving active therapy (hazard ratio of 1.98, 95% CI 1.19-3.28). At study end, active therapy was also not associated with a significant benefit in preventing thrombosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among hemodialysis patients at high risk of initial graft failure who are also at low risk for bleeding, we suggest the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . We give extended release dipyridamole (200 mg twice daily) plus aspirin (25 mg twice daily). Patients at high risk of graft failure are those with a history of early thrombosis (within three months of surgery) of a previous AV graft. However, it is reasonable to forego such therapy given the uncertainty concerning the benefit and the increased risk of bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SYSTEMIC ANTICOAGULATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    does not prevent thrombosis and failure of an AV graft and is associated with an increased risk of bleeding. This was best shown in a multicenter clinical study in which 107 patients with new grafts were randomly assigned to receive low-intensity warfarin (target INR 1.5-1.9) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7942/abstract/14\">",
"     14",
"    </a>",
"    ]. There was no difference in graft thrombosis between the two groups. However, 10 percent of the patients receiving warfarin developed major hemorrhage despite close monitoring of the INR.",
"   </p>",
"   <p>",
"    Although no well designed randomized studies have been performed, some retrospective and observational studies have also reported an increased morbidity and mortality among dialysis patients who were administered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for a number of different indications [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7942/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In the general hemodialysis patient, we do not recommend warfarin for the prevention of thrombosis and failure of an AV graft.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Hypercoagulable states",
"    </span>",
"    &nbsp;&mdash;&nbsp;However, unlike the general hemodialysis patient, some patients with thrombosis have an underlying hypercoagulable state, which is associated with early and rapid graft thrombosis. Thus, among patients with very early (within 24 to 48 hours of surgery) or recurrent graft thrombosis in the absence of underlying stenosis, we initiate an evaluation for a coagulation abnormality or hypercoagulable state given that such patients are increased risk of abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7942/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. As an example, antiphospholipid antibodies (aPL) such as lupus anticoagulants (LA) and anticardiolipin antibodies (aCL) increase the risk of access thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7942/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. A report of 97 patients on maintenance hemodialysis noted that those with LA activity (16.5 percent) had a higher frequency of vascular access thrombosis than patients without an LA (62 versus 26 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7942/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, the assessment should include an evaluation for abnormalities in protein S, protein C, and antithrombin-3 as well as the presence of antiphospholipid antibodies. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=see_link\">",
"     \"Evaluation of the patient with established venous thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=see_link\">",
"     \"Protein C deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27096?source=see_link\">",
"     \"Diagnosis of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although entirely opinion based, we consider administering",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    to selected patients with a hypercoagulable state. Specific management issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=see_link\">",
"     \"Management of inherited thrombophilia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=see_link\">",
"     \"Treatment of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     FISH OIL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fish oil, or more specifically omega-3 fatty acids, inhibit cyclooxygenase (thereby prolonging bleeding times), and may dampen intimal hyperplasia in vein grafts. The efficacy of this agent in preventing thrombosis was first assessed prospectively among 24 patients with PTFE grafts randomly assigned to either 4000 mg of fish oil or 4000 mg of control oil [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7942/abstract/21\">",
"     21",
"    </a>",
"    ]. At 12 months, the primary patency rate was significantly higher among those administered fish oil (77 versus 15 percent).",
"   </p>",
"   <p>",
"    The effect of fish oil was subsequently assessed in a randomized multicenter study of 201 patients who were assigned to receive fish oil (4",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    or placebo starting 7 days after graft creation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7942/abstract/22\">",
"     22",
"    </a>",
"    ]. At 12 months of follow-up, the proportion of individuals who had graft thrombosis or radiological or surgical intervention was lower among patients who were taking fish oil, although the difference was not statistically significant (48 versus 62 percent among the fish oil and placebo groups, respectively, with relative risk of 0.78, 95% CI 0.60-1.03).",
"   </p>",
"   <p>",
"    Compared with placebo, fish oil was associated with the following predefined secondary endpoints:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A lower rate of graft failure (5.95 versus 3.43 per 1000 access-days, respectively, incidence rate ratio (IRR) 0.58, 95% CI 0.44-0.75).",
"     </li>",
"     <li>",
"      Fewer thromboses (3.41 versus 1.71 per 1000 access-days, respectively, IRR 0.50, 95% CI 0.35-0.72).",
"     </li>",
"     <li>",
"      Fewer interventions (4.92 versus 2.89 per 1000 access-days, respectively, IRR 0.59, 95% CI 0.44-0.78).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, as has been observed in prior studies, fish oil was associated with a better cardiovascular event-free survival and lower mean systolic blood pressure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36330?source=see_link&amp;anchor=H5#H5\">",
"     \"Fish oil and marine omega-3 fatty acids\", section on 'Blood pressure and systemic vascular resistance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36330?source=see_link&amp;anchor=H13#H13\">",
"     \"Fish oil and marine omega-3 fatty acids\", section on 'Cardiovascular outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, despite the lack of statistical difference in the primary outcome, the administration of fish oil was associated with clinically relevant benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7942/abstract/23\">",
"     23",
"    </a>",
"    ]. Based upon these data, among patients who have an AV graft, we suggest the administration of fish oil 4",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    in order to reduce the risk of graft thrombosis. Fish oil in this study also reduced blood pressure and occurrence of some adverse cardiovascular disease events. Although the studied cohort was limited to patients with new AV grafts, the benefits provided by fish oil, including cardiovascular effects, may extend to all patients with AV grafts, justifying its use among all such patients. Further studies are needed to evaluate the effect of fish oil on existing grafts that are not newly placed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vascular access stenosis of a hemodialysis arteriovenous (AV) graft is initiated by endothelial cell injury, which leads to the upregulation of adhesion molecules on the endothelial cell surface. Although unproven, measures aimed to prevent neointimal hyperplasia as well as other pharmacologic agents that address some of the elements underlying vascular stenosis may help prevent stenosis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among all patients who have an AV graft, we suggest the administration of fish oil (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The administration of fish oil (4",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      may reduce the risk of graft thrombosis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Fish oil'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among hemodialysis patients at high risk of initial graft failure who are also at low risk for bleeding, we suggest the administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients at high risk of graft failure are those with a history of early thrombosis (within three months of surgery) of a previous AV graft. It is reasonable for patients to forego such therapy given the uncertainty concerning the benefit and the increased risk of bleeding. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Antiplatelet agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among the general hemodialysis patient, we do not recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      for the prevention of thrombosis and failure of an AV graft (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Among hemodialysis patients with very early (within 24 to 48 hours of surgery) or recurrent graft thrombosis in the absence of underlying stenosis, we initiate an evaluation for a coagulation abnormality or hypercoagulable state. Among selected patients with such abnormalities, warfarin may be appropriate. Specific management issues are discussed separately. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Systemic anticoagulation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Hypercoagulable states'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7942/abstract/1\">",
"      Swedberg SH, Brown BG, Sigley R, et al. Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients. Clinical, immunocytochemical, light and electron microscopic assessment. Circulation 1989; 80:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7942/abstract/2\">",
"      Rekhter M, Nicholls S, Ferguson M, Gordon D. Cell proliferation in human arteriovenous fistulas used for hemodialysis. Arterioscler Thromb 1993; 13:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7942/abstract/3\">",
"      Stracke S, Konner K, K&ouml;stlin I, et al. Increased expression of TGF-beta1 and IGF-I in inflammatory stenotic lesions of hemodialysis fistulas. Kidney Int 2002; 61:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7942/abstract/4\">",
"      Sterpetti AV, Cucina A, Santoro L, et al. Modulation of arterial smooth muscle cell growth by haemodynamic forces. Eur J Vasc Surg 1992; 6:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7942/abstract/5\">",
"      Hsieh HJ, Li NQ, Frangos JA. Shear stress increases endothelial platelet-derived growth factor mRNA levels. Am J Physiol 1991; 260:H642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7942/abstract/6\">",
"      Hofstra L, Bergmans DC, Hoeks AP, et al. Mismatch in elastic properties around anastomoses of interposition grafts for hemodialysis access. J Am Soc Nephrol 1994; 5:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7942/abstract/7\">",
"      Himmelfarb J. Pharmacologic prevention of vascular access stenosis. Curr Opin Nephrol Hypertens 1999; 8:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7942/abstract/8\">",
"      Chang CJ, Ko PJ, Hsu LA, et al. Highly increased cell proliferation activity in the restenotic hemodialysis vascular access after percutaneous transluminal angioplasty: implication in prevention of restenosis. Am J Kidney Dis 2004; 43:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7942/abstract/9\">",
"      Domoto DT, Bauman JE, Joist JH. Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis vascular access thrombosis. Thromb Res 1991; 62:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7942/abstract/10\">",
"      Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM. Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study. Kidney Int 1994; 45:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7942/abstract/11\">",
"      Kaufman JS, O'Connor TZ, Zhang JH, et al. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol 2003; 14:2313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7942/abstract/12\">",
"      Dixon BS, Beck GJ, Vazquez MA, et al. Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med 2009; 360:2191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7942/abstract/13\">",
"      Dixon BS, Beck GJ, Dember LM, et al. Use of aspirin associates with longer primary patency of hemodialysis grafts. J Am Soc Nephrol 2011; 22:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7942/abstract/14\">",
"      Crowther MA, Clase CM, Margetts PJ, et al. Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial. J Am Soc Nephrol 2002; 13:2331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7942/abstract/15\">",
"      Chan KE, Lazarus JM, Thadhani R, Hakim RM. Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol 2009; 20:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7942/abstract/16\">",
"      Morgan CL, McEwan P, Tukiendorf A, et al. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res 2009; 124:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7942/abstract/17\">",
"      Schwab SJ, Harrington JT, Singh A, et al. Vascular access for hemodialysis. Kidney Int 1999; 55:2078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7942/abstract/18\">",
"      Brunet P, Aillaud MF, San Marco M, et al. Antiphospholipids in hemodialysis patients: relationship between lupus anticoagulant and thrombosis. Kidney Int 1995; 48:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7942/abstract/19\">",
"      Prakash R, Miller CC 3rd, Suki WN. Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis. Am J Kidney Dis 1995; 26:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7942/abstract/20\">",
"      Molino D, De Lucia D, Marotta R, et al. In uremia, plasma levels of anti-protein C and anti-protein S antibodies are associated with thrombosis. Kidney Int 2005; 68:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7942/abstract/21\">",
"      Schmitz PG, McCloud LK, Reikes ST, et al. Prophylaxis of hemodialysis graft thrombosis with fish oil: double-blind, randomized, prospective trial. J Am Soc Nephrol 2002; 13:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7942/abstract/22\">",
"      Lok CE, Moist L, Hemmelgarn BR, et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA 2012; 307:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7942/abstract/23\">",
"      Dixon BS. Fish oil and hemodialysis graft patency: does time matter? JAMA 2012; 307:1859.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1950 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-192C8F5B95-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_48_7942=[""].join("\n");
var outline_f7_48_7942=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANTIPLATELET AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SYSTEMIC ANTICOAGULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Hypercoagulable states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      FISH OIL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23816?source=related_link\">",
"      Arteriovenous fistulas and grafts for chronic hemodialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27096?source=related_link\">",
"      Diagnosis of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=related_link\">",
"      Evaluation of the patient with established venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36330?source=related_link\">",
"      Fish oil and marine omega-3 fatty acids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=related_link\">",
"      Management of inherited thrombophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=related_link\">",
"      Protein C deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=related_link\">",
"      Treatment of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_48_7943="Stone related cystic duct leak";
var content_f7_48_7943=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77959%7EGAST%2F66681%7EGAST%2F67568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77959%7EGAST%2F66681%7EGAST%2F67568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stone-related cystic duct stump leak after cholecystectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 266px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    ERCP demonstrates an incomplete cholecystectomy and cystic duct leak with retained common bile duct stones.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Bourke, MBBS, FRACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    T tube-related leak after cholecystectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    ERCP reveals a leak emanating from the T-tube site (arrow). A stent has been placed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Bourke, MBBS, FRACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Right hepatic radical bile leak after cholecystectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 313px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    ERCP shows extravasation of contrast from a right hepatic bile duct radical (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Bourke, MBBS, FRACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_48_7943=[""].join("\n");
var outline_f7_48_7943=null;
var title_f7_48_7944="Metformin: Drug information";
var content_f7_48_7944=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Metformin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/22/358?source=see_link\">",
"    see \"Metformin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/59/13238?source=see_link\">",
"    see \"Metformin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F193858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fortamet&reg;;",
"     </li>",
"     <li>",
"      Glucophage&reg;;",
"     </li>",
"     <li>",
"      Glucophage&reg; XR;",
"     </li>",
"     <li>",
"      Glumetza&reg;;",
"     </li>",
"     <li>",
"      Riomet&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F193859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Metformin&reg;;",
"     </li>",
"     <li>",
"      Ava-Metformin;",
"     </li>",
"     <li>",
"      CO Metformin;",
"     </li>",
"     <li>",
"      Dom-Metformin;",
"     </li>",
"     <li>",
"      Glucophage&reg;;",
"     </li>",
"     <li>",
"      Glumetza&reg;;",
"     </li>",
"     <li>",
"      Glycon;",
"     </li>",
"     <li>",
"      JAMP-Metformin;",
"     </li>",
"     <li>",
"      JAMP-Metformin Blackberry;",
"     </li>",
"     <li>",
"      Med-Metformin;",
"     </li>",
"     <li>",
"      Mylan-Metformin;",
"     </li>",
"     <li>",
"      Novo-Metformin;",
"     </li>",
"     <li>",
"      Nu-Metformin;",
"     </li>",
"     <li>",
"      PHL-Metformin;",
"     </li>",
"     <li>",
"      PMS-Metformin;",
"     </li>",
"     <li>",
"      PRO-Metformin;",
"     </li>",
"     <li>",
"      Q-Metformin;",
"     </li>",
"     <li>",
"      RAN&trade;-Metformin;",
"     </li>",
"     <li>",
"      ratio-Metformin;",
"     </li>",
"     <li>",
"      Riva-Metformin;",
"     </li>",
"     <li>",
"      Sandoz-Metformin FC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F193907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiabetic Agent, Biguanide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F193863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Management of type 2 diabetes mellitus:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Allow 1-2 weeks between dose titrations: Generally, clinically significant responses are not seen at doses &lt;1500 mg daily; however, a lower recommended starting dose and gradual increased dosage is recommended to minimize gastrointestinal symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Immediate release tablet or solution:",
"     </i>",
"     Adults &ge;17 years: Initial: 500 mg twice daily",
"     <b>",
"      or",
"     </b>",
"     850 mg once daily; titrate in increments of 500 mg weekly or 850 mg every other week; may also titrate from 500 mg twice a day to 850 mg twice a day after 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If a dose &gt;2000 mg daily is required, it may be better tolerated in 3 divided doses. Maximum recommended dose: 2550 mg daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Extended release tablet:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     If glycemic control is not achieved at maximum dose, may divide dose and administer twice daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Fortamet&reg;: Initial: 500-1000 mg once daily; dosage may be increased by 500 mg weekly; maximum dose: 2500 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Glucophage&reg; XR: Initial: 500 mg once daily; dosage may be increased by 500 mg weekly; maximum dose: 2000 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Glumetza&reg;: Initial: 1000 mg once daily; dosage may be increased by 500 mg weekly; maximum dose: 2000 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Transfer from other antidiabetic agents:",
"     </b>",
"     No transition period is generally necessary except when transferring from chlorpropamide. When transferring from chlorpropamide, care should be exercised during the first 2 weeks because of the prolonged retention of chlorpropamide in the body, leading to overlapping drug effects and possible hypoglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concomitant metformin and oral sulfonylurea therapy:",
"     </b>",
"     If patients have not responded to 4 weeks of the maximum dose of metformin monotherapy, consider a gradual addition of an oral sulfonylurea, even if prior primary or secondary failure to a sulfonylurea has occurred. Continue metformin at the maximum dose. If adequate response has not occurred following 3 months of metformin and sulfonylurea combination therapy, consider switching to insulin with or without metformin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Failed sulfonylurea therapy:",
"     </b>",
"     Patients with prior failure on glyburide may be treated by gradual addition of metformin. Initiate with glyburide 20 mg and metformin 500 mg daily. Metformin dosage may be increased by 500 mg/day at weekly intervals, up to a maximum metformin dose (dosage of glyburide maintained at 20 mg daily).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concomitant metformin and insulin therapy:",
"     </b>",
"     Initial: 500 mg metformin once daily, continue current insulin dose; increase by 500 mg metformin weekly until adequate glycemic control is achieved",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maximum daily dose: Immediate release and solution: 2550 mg metformin; Extended release: 2000-2500 mg (varies by product)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Decrease insulin dose 10% to 25% when FPG &lt;120 mg/dL; monitor and make further adjustments as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Type 2 diabetes prevention (unlabeled use):",
"     </b>",
"     <i>",
"      Immediate release tablet or solution:",
"     </i>",
"     Oral: Initial: 850 mg once daily; Target: 850 mg twice daily (Knowler, 2002)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F193885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/59/13238?source=see_link\">",
"      see \"Metformin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Management of type 2 diabetes mellitus:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Allow 1-2 weeks between dose titrations: Generally, clinically significant responses are not seen at doses &lt;1500 mg daily; however, a lower recommended starting dose and gradual increased dosage is recommended to minimize gastrointestinal symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Immediate release tablet or solution:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 10-16 years: Initial: 500 mg twice daily; increases in daily dosage should be made in increments of 500 mg at weekly intervals, given in divided doses, up to a maximum of 2000 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;17 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Extended release tablet:",
"     </i>",
"     Children &ge;17 years:",
"     <b>",
"      Note:",
"     </b>",
"     If glycemic control is not achieved at maximum dose, may divide dose and administer twice daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fortamet&reg;: Initial: 500-1000 mg once daily; dosage may be increased by 500 mg weekly; maximum dose: 2500 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Glucophage&reg; XR: Initial: 500 mg once daily; dosage may be increased by 500 mg weekly; maximum dose: 2000 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F193864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The initial and maintenance dosing should be conservative, due to the potential for decreased renal function. Generally, elderly patients should",
"     <b>",
"      not",
"     </b>",
"     be titrated to the maximum dose of metformin. Do not use in patients &ge;80 years of age unless normal renal function has been established.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F193865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The plasma and blood half-life of metformin is prolonged and the renal clearance is decreased in proportion to the decrease in creatinine clearance. Per the manufacturer, metformin is contraindicated in the presence of renal dysfunction defined as a serum creatinine &ge;1.5 mg/dL in males, or &ge;1.4 mg/dL in females and in patients with abnormal clearance. The Canadian labeling recommends that metformin be avoided in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F193866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid metformin; liver disease is a risk factor for the development of lactic acidosis during metformin therapy.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F193832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Riomet&reg;: 100 mg/mL (118 mL, 473 mL) [dye free, ethanol free, sugar free; contains saccharin; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 500 mg, 850 mg, 1000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Glucophage&reg;: 500 mg, 850 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Glucophage&reg;: 1000 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as hydrochloride: 500 mg, 750 mg, 1000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fortamet&reg;: 500 mg, 1000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Glucophage&reg; XR: 500 mg, 750 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Glumetza&reg;: 500 mg, 1000 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F193817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes solution",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F193837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with a meal (to decrease GI upset).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release: Swallow whole; do not crush, break, or chew. Administer once daily doses with the evening meal. Fortamet&reg; should also be administered with a full glass of water.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F193836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of type 2 diabetes mellitus (noninsulin dependent, NIDDM) when hyperglycemia cannot be managed with diet and exercise alone.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F193903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gestational diabetes mellitus (GDM); polycystic ovary syndrome (PCOS); prevention of type 2 diabetes mellitus",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F193915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       MetFORMIN may be confused with metroNIDAZOLE",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Glucophage&reg; may be confused with Glucotrol&reg;, Glutofac&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Dianben [Spain] may be confused with Diovan brand name for valsartan [U.S., Canada, and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F193905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (IR tablet: 12% to 53%; ER tablet: 10% to 17%), nausea/vomiting (IR tablet: 7% to 26%; ER tablet: 7% to 9%), flatulence (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest discomfort, flushing, palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (6%), chills, dizziness, lightheadedness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Indigestion (7%), abdominal discomfort (6%), abdominal distention, abnormal stools, constipation, dyspepsia/ heartburn, taste disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Decreased vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     levels (7%), increased diaphoresis, flu-like syndrome, nail disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Lactic acidosis, leukocytoclastic vasculitis, megaloblastic anemia, pneumonitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F193840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to metformin or any component of the formulation; renal disease or renal dysfunction (serum creatinine &ge;1.5 mg/dL in males or &ge;1.4 mg/dL in females) or abnormal creatinine clearance from any cause, including shock, acute myocardial infarction, or septicemia; acute or chronic metabolic acidosis with or without coma (including diabetic ketoacidosis)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Temporarily discontinue in patients undergoing radiologic studies in which intravascular iodinated contrast media are utilized.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F193821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular mortality: Administration of oral antidiabetic drugs has been reported to be associated with increased cardiovascular mortality; metformin does not appear to share this risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactic acidosis:",
"     <b>",
"      [U.S. Boxed Warning]: Lactic acidosis is a rare, but potentially severe consequence of therapy with metformin.",
"     </b>",
"     Lactic acidosis should be suspected in any patient with diabetes receiving metformin with evidence of acidosis but without evidence of ketoacidosis. Discontinue metformin in clinical situations predisposing to hypoxemia, including conditions such as cardiovascular collapse, respiratory failure, acute myocardial infarction, acute congestive heart failure, and septicemia. The risk of accumulation and lactic acidosis increases with the degree of impairment of renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Use caution in patients with congestive heart failure requiring pharmacologic management, particularly in patients with unstable or acute heart failure; risk of lactic acidosis may be increased secondary to hypoperfusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Avoid use in patients with impaired liver function due to potential for lactic acidosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Metformin is substantially excreted by the kidney; patients with renal function below the limit of normal for their age should not receive therapy. Use of concomitant medications that may affect renal function (ie, affect tubular secretion) may also affect metformin disposition. Metformin should be withheld in patients with dehydration and/or prerenal azotemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Stress-related states: It may be necessary to discontinue metformin and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Metformin should not be initiated in patients &ge;80 years of age unless normal renal function is confirmed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extended release tablet: Insoluble tablet shell (Glumetza&reg; 1000 mg tablet) may remain intact and be visible in the stool. Other extended released tablets (Fortamet&reg;, Glucophage&reg; XR, Glumetza&reg; 500 mg) may appear in the stool as a soft mass resembling the tablet.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol use: Instruct patients to avoid excessive acute or chronic ethanol use; ethanol may potentiate metformin's effect on lactate metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Iodinated contrast: Therapy should  be temporarily discontinued prior to or at the time of  intravascular administration of iodinated contrast media (potential for acute alteration in renal function). Metformin should be withheld for 48 hours after the radiologic study and restarted only after renal function has been confirmed as normal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical procedures: Therapy should be suspended for any surgical procedures (resume only after normal oral intake resumed and normal renal function is verified).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F193826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk of developing lactic acidosis may be increased.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalexin: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dalfampridine: May increase the serum concentration of MetFORMIN. MetFORMIN may increase the serum concentration of Dalfampridine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: MetFORMIN may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glycopyrrolate: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iodinated Contrast Agents: May enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis. Management: Withhold metformin from all patients receiving intravascular iodinated contrast agents prior to or at the time of the procedure and for at least 48 hrs thereafter.  Document adequate renal function before restarting metformin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: May increase the serum concentration of MetFORMIN. Management: The lamotrigine Canadian product monograph states that coadministration of these drugs is not recommended.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trospium: MetFORMIN may decrease the serum concentration of Trospium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F193854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid or limit ethanol (incidence of lactic acidosis may be increased; may cause hypoglycemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Food decreases the extent and slightly delays the absorption. May decrease absorption of vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     and/or folic acid.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Caution with chromium, garlic, gymnema (may cause hypoglycemia).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F193828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F193843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal studies; therefore, metformin is classified as pregnancy category B. Metformin has been found to cross the placenta in concentrations which may be comparable to those found in the maternal plasma. Pharmacokinetic studies suggest that clearance of metformin may be increased during pregnancy and dosing may need adjusted in some women when used during the third trimester.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Fetal, neonatal, and maternal outcomes have been evaluated following maternal use of metformin for the treatment of GDM and type 2 diabetes. Available information suggests that metformin use during pregnancy may be safe as long as good glycemic control is maintained; however, many studies used metformin during the second or third trimester only. Maternal hyperglycemia can be associated with adverse effects in the fetus, including macrosomia, neonatal hyperglycemia, and hyperbilirubinemia; the risk of congenital malformations is increased when the Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     is above the normal range. Diabetes can also be associated with adverse effects in the mother. Poorly-treated diabetes may cause end-organ damage that may negatively affect obstetric outcomes. Physiologic glucose levels should be maintained prior to and during pregnancy to decrease the risk of adverse events in the mother and the fetus. Until additional safety and efficacy data are obtained, the use of oral agents is generally not recommended as routine management of GDM or type 2 diabetes mellitus during pregnancy. Insulin is the drug of choice for the control of diabetes mellitus during pregnancy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Metformin has also been evaluated for the treatment of PCOS, a syndrome which may exhibit oligomenorrhea and, in some women, hyperinsulinemia. It is not recommended as first-line therapy; when used to treat infertility related to PCOS, current guidelines restrict the use of metformin to women with glucose intolerance. Because ovulation rates will likely improve in women with PCOS who are taking metformin, appropriate contraceptive measures should be discussed in women who are not attempting to conceive.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F193870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F193844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Low amounts of metformin (generally &le;1% of the weight-adjusted maternal dose) are excreted into breast milk. Breast-feeding is not recommended by the manufacturer. Because breast milk concentrations of metformin stay relatively constant, avoiding nursing around peak plasma concentrations in the mother would not be helpful in reducing metformin exposure to the infant. Growth and development were not affected in infants born to mothers with PCOS and who took metformin while breast-feeding.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F193845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drug may cause GI upset; take with food (to decrease GI upset). Take at the same time(s) each day. Dietary modification based on ADA recommendations is a part of therapy. Monitor for signs and symptoms of vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     and/or folic acid deficiency; supplementation may be required.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F193842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Riomet Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg/5 mL (118 mL): $55.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Fortamet Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (60): $837.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 mg (60): $837.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Glucophage XR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $114.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     750 mg (100): $171.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Glumetza Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $552.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 mg (90): $1074.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (MetFORMIN HCl ER (OSM) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (60): $344.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 mg (60): $628.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (MetFORMIN HCl ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $74.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     750 mg (100): $119.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Glucophage Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $111.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     850 mg (100): $190.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 mg (100): $230.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (MetFORMIN HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $70.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     850 mg (100): $119.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 mg (100): $144.99",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F193830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Urine for glucose and ketones, fasting blood glucose, hemoglobin A",
"     <sub>",
"      1c",
"     </sub>",
"     , and fructosamine. Initial and periodic monitoring of hematologic parameters (eg, hemoglobin/hematocrit and red blood cell indices) and renal function should be performed, at least annually. While megaloblastic anemia has been rarely seen with metformin, if suspected, check vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     and folate if anemia is present.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F193833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak postprandial capillary blood glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F193846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adecco (ID);",
"     </li>",
"     <li>",
"      Ansures (MY, PH);",
"     </li>",
"     <li>",
"      Benofomin (ID);",
"     </li>",
"     <li>",
"      Biguax (CO);",
"     </li>",
"     <li>",
"      Dabex (MX);",
"     </li>",
"     <li>",
"      Deson (TH);",
"     </li>",
"     <li>",
"      Diabemet (MY);",
"     </li>",
"     <li>",
"      Diabetase (DE);",
"     </li>",
"     <li>",
"      Diabetmin (HK, MY);",
"     </li>",
"     <li>",
"      Diabetmin Retard (HK);",
"     </li>",
"     <li>",
"      Diabetol (PY);",
"     </li>",
"     <li>",
"      Diabex (AU);",
"     </li>",
"     <li>",
"      Diabex XR (AU);",
"     </li>",
"     <li>",
"      Diafat (PH);",
"     </li>",
"     <li>",
"      Diaformin (AU, HK);",
"     </li>",
"     <li>",
"      Diaformina (UY);",
"     </li>",
"     <li>",
"      Diaformina LP (UY);",
"     </li>",
"     <li>",
"      Dianben (ES);",
"     </li>",
"     <li>",
"      Diaslim (TH);",
"     </li>",
"     <li>",
"      Diformin (FI);",
"     </li>",
"     <li>",
"      Diformin Retard (FI);",
"     </li>",
"     <li>",
"      Dimefor (BR, CO, MX, PE);",
"     </li>",
"     <li>",
"      Emnorm (NZ);",
"     </li>",
"     <li>",
"      Euform Retard (PH);",
"     </li>",
"     <li>",
"      Formet (AU, MY);",
"     </li>",
"     <li>",
"      Formin (IN);",
"     </li>",
"     <li>",
"      Fornidd (PH);",
"     </li>",
"     <li>",
"      Glafornil (CN);",
"     </li>",
"     <li>",
"      Glavis (KP);",
"     </li>",
"     <li>",
"      Glibudon (TW);",
"     </li>",
"     <li>",
"      Glicenex (EC);",
"     </li>",
"     <li>",
"      Gliformin (CO);",
"     </li>",
"     <li>",
"      Glisulin XR (CR, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Glu-A (KP);",
"     </li>",
"     <li>",
"      Gluco (TH);",
"     </li>",
"     <li>",
"      Glucodown (KP);",
"     </li>",
"     <li>",
"      Glucofage (EC, VE);",
"     </li>",
"     <li>",
"      Glucofor (ID);",
"     </li>",
"     <li>",
"      Glucoform (PH);",
"     </li>",
"     <li>",
"      Glucoformin (BR);",
"     </li>",
"     <li>",
"      Glucoles (TH);",
"     </li>",
"     <li>",
"      Glucomet (AU, HK, SG);",
"     </li>",
"     <li>",
"      Glucomin (IL);",
"     </li>",
"     <li>",
"      Glucomine (TW);",
"     </li>",
"     <li>",
"      Glucon (MY);",
"     </li>",
"     <li>",
"      Glucophage (AE, AR, AT, AU, BB, BE, BF, BH, BJ, BM, BS, BZ, CH, CI, CL, CY, CZ, DK, EE, EG, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, HR, ID, IE, IL, IN, IQ, IR, IT, JM, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NO, OM, PE, PH, PK, PT, QA, RU, SA, SC, SD, SE, SL, SN, SR, SY, TN, TR, TT, TW, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Glucophage Forte (CZ, NL, PH);",
"     </li>",
"     <li>",
"      Glucophage Retard (IL);",
"     </li>",
"     <li>",
"      Glucophage SR (GB, IE);",
"     </li>",
"     <li>",
"      Glucophage XR (HK, MY);",
"     </li>",
"     <li>",
"      Glucophage-Mite (DE);",
"     </li>",
"     <li>",
"      Glucotika (ID);",
"     </li>",
"     <li>",
"      Gludepatic (ID);",
"     </li>",
"     <li>",
"      Glufor (ID, IL);",
"     </li>",
"     <li>",
"      Glumet (MY, PH);",
"     </li>",
"     <li>",
"      Glumet DC (MY);",
"     </li>",
"     <li>",
"      Glumet Forte (HK);",
"     </li>",
"     <li>",
"      Glumin (ID);",
"     </li>",
"     <li>",
"      Glumin XR (ID);",
"     </li>",
"     <li>",
"      Glunor (PE);",
"     </li>",
"     <li>",
"      Glupa (KP);",
"     </li>",
"     <li>",
"      Glustress (TH);",
"     </li>",
"     <li>",
"      Glyciphage (IN);",
"     </li>",
"     <li>",
"      Glycomet (SG);",
"     </li>",
"     <li>",
"      Glycomin (KP);",
"     </li>",
"     <li>",
"      Glyformin (TW);",
"     </li>",
"     <li>",
"      Glymet (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Guamet (HK);",
"     </li>",
"     <li>",
"      I-Max (PH);",
"     </li>",
"     <li>",
"      Insumed (PH);",
"     </li>",
"     <li>",
"      Islotin (AR);",
"     </li>",
"     <li>",
"      Maformin (TH);",
"     </li>",
"     <li>",
"      Medfort (PE);",
"     </li>",
"     <li>",
"      Meglucon (DE);",
"     </li>",
"     <li>",
"      Melbin (HK, JP);",
"     </li>",
"     <li>",
"      Merckformin (HU);",
"     </li>",
"     <li>",
"      Mescorit (DE);",
"     </li>",
"     <li>",
"      Metchek (NZ);",
"     </li>",
"     <li>",
"      Metex XR (AU);",
"     </li>",
"     <li>",
"      Metfogamma (DE);",
"     </li>",
"     <li>",
"      Metforal (CR, DO, GT, HN, IT, NI, PA, SG, SV);",
"     </li>",
"     <li>",
"      Miformin (TH);",
"     </li>",
"     <li>",
"      Neoform (PH);",
"     </li>",
"     <li>",
"      Orabet (AT, DK, GB, IE);",
"     </li>",
"     <li>",
"      Perdial (DO, GT, HN, NI, SV);",
"     </li>",
"     <li>",
"      Quexel (CR, DO, GT, HN, PA, SV);",
"     </li>",
"     <li>",
"      Risidon (PT);",
"     </li>",
"     <li>",
"      Siamformet (TH);",
"     </li>",
"     <li>",
"      Siofor (BG, DE, PL);",
"     </li>",
"     <li>",
"      Stagid (PT);",
"     </li>",
"     <li>",
"      Thiabet (DE);",
"     </li>",
"     <li>",
"      Walaphage (IN);",
"     </li>",
"     <li>",
"      Wonformin (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F193820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreases hepatic glucose production, decreasing intestinal absorption of glucose and improves insulin sensitivity (increases peripheral glucose uptake and utilization)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F193839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Within days; maximum effects up to 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 654 &plusmn; 358 L; partitions into erythrocytes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Negligible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Not metabolized by the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Absolute: Fasting: 50% to 60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Plasma: 4-9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Immediate release: 2-3 hours; Extended release: 7 hours (range: 4-8 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (90% as unchanged drug; active secretion)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Association of Clinical Endocrinologists Polycystic Ovary Syndrome Writing Committee,  &ldquo;American Association of Clinical Endocrinologists Position Statement on Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2005, 11(2):126-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7944/abstract-text/15915567/pubmed\" id=\"15915567\" target=\"_blank\">",
"        15915567",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7944/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bailey CJ and Turner RC, &ldquo;Metformin,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 334(9):574-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7944/abstract-text/8569826/pubmed\" id=\"8569826\" target=\"_blank\">",
"        8569826",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, \"Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada,\"",
"      <i>",
"       Can J Diabetes",
"      </i>",
"      , 20078, 32(suppl 1):1-201.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coetzee EJ and Jackson WP, &ldquo;Metformin in Management of Pregnant Insulin-Independent Diabetics,&rdquo;",
"      <i>",
"       Diabetologia",
"      </i>",
"      , 1979, 16(4):241-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7944/abstract-text/428695/pubmed\" id=\"428695\" target=\"_blank\">",
"        428695",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeFronzo RA, &ldquo;Pharmacologic Therapy for Type 2 Diabetes Mellitus,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1999, 131(4):281-303.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7944/abstract-text/10454950/pubmed\" id=\"10454950\" target=\"_blank\">",
"        10454950",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dunn CJ and Peters DH, &ldquo;Metformin: A Review of Its Pharmacologic Properties and Therapeutic Use in Diabetes Mellitus,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1995, 49(5):721-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7944/abstract-text/7601013/pubmed\" id=\"7601013\" target=\"_blank\">",
"        7601013",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Handelsman Y, Mechanick JI, Blonde L, et al, &ldquo;American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2011, 17(Suppl 2):1-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7944/abstract-text/21474420/pubmed\" id=\"21474420\" target=\"_blank\">",
"        21474420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hughes RC and Rowan JA, &ldquo;Pregnancy in Women With Type 2 Diabetes: Who Takes Metformin and What Is the Outcome?&rdquo;",
"      <i>",
"       Diabet Med",
"      </i>",
"      , 2006, 23(3):318-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7944/abstract-text/16492217/pubmed\" id=\"16492217\" target=\"_blank\">",
"        16492217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Josephkutty S and Potter JM, &ldquo;Comparison of Tolbutamide and Metformin in Elderly Diabetic Patients,&rdquo;",
"      <i>",
"       Diabet Med",
"      </i>",
"      , 1990, 7(16):510-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7944/abstract-text/2142054/pubmed\" id=\"2142054\" target=\"_blank\">",
"        2142054",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kirkman M, Briscoe VJ, Clark N, et al, \"Diabetes in Older Adults: A Consensus Report,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012; doi: 10.1111/jgs.12035.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7944/abstract-text/23106132/pubmed\" id=\"23106132\" target=\"_blank\">",
"        23106132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Knowler WC, Barrett-Connor E, Fowler SE, et al, \"Reduction in the Incidence of Type 2 Diabetes With Lifestyle Intervention or Metformin,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2002, 346(6):393-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7944/abstract-text/11832527/pubmed\" id=\"11832527\" target=\"_blank\">",
"        11832527",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lalau JD, Vermersch A, Hary L, et al, &ldquo;Type 2 Diabetes in the Elderly: An Assessment of Metformin,&rdquo;",
"      <i>",
"       Int J Clin Pharmacol Ther Toxicol",
"      </i>",
"      , 1990, 28(8):329-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7944/abstract-text/2272714/pubmed\" id=\"2272714\" target=\"_blank\">",
"        2272714",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nestler JE, &ldquo;Metformin for the Treatment of the Polycystic Ovary Syndrome,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 358(1):47-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7944/abstract-text/18172174/pubmed\" id=\"18172174\" target=\"_blank\">",
"        18172174",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7944/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodbard HW, Jellinger PS, Davidson JA, et al, &ldquo;Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2009, 15(6):540-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7944/abstract-text/19858063/pubmed\" id=\"19858063\" target=\"_blank\">",
"        19858063",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rowan JA,  Hague WM, Gao W, et  al, &ldquo;Metformin Versus Insulin for the Treatment of Gestational Diabetes,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 358(19):2003-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7944/abstract-text/18463376/pubmed\" id=\"18463376\" target=\"_blank\">",
"        18463376",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7944/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9621 Version 52.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.80.101-F770B2E4D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_48_7944=[""].join("\n");
var outline_f7_48_7944=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709034\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193858\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193859\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193907\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193863\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193885\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193864\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193865\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193866\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193832\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193817\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193837\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193836\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193903\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193915\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193905\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193840\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193821\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299680\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193826\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193854\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193828\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193843\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193870\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193844\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193845\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193842\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193830\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193833\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193846\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193820\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193839\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9621\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9621|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/22/358?source=related_link\">",
"      Metformin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/59/13238?source=related_link\">",
"      Metformin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_48_7945="Occupational rhinitis";
var content_f7_48_7945=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Occupational rhinitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/48/7945/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/48/7945/contributors\">",
"     Jennifer Gentner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/48/7945/contributors\">",
"     Raymond Slavin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/48/7945/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/48/7945/contributors\">",
"     Jonathan Corren, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/48/7945/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/48/7945/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/48/7945/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occupational Rhinitis (OR) may be defined as \"an inflammatory condition of the nose, which is characterized by intermittent or persistent symptoms (ie, nasal congestion, sneezing, rhinorrhea, itching)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    variable nasal airflow limitation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypersecretion, due to causes and conditions attributable to a particular work environment and not to stimuli encountered outside the workplace\" [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/1\">",
"     1",
"    </a>",
"    ]. Occupational rhinitis (OR) is different from work-exacerbated rhinitis (WER), which is pre-existing or concurrent (allergic or nonallergic) rhinitis that is worsened by, but not caused by, workplace exposures. OR can develop in response to allergens, inhaled irritants, or corrosive gases.",
"   </p>",
"   <p>",
"    Occupational rhinitis may have a profound effect on the worker, resulting in performance deficits, reduced productivity, and psychosocial problems. OR often coexists with occupational asthma.",
"   </p>",
"   <p>",
"    The epidemiology, pathophysiology, clinical manifestations, diagnosis, and management of OR will be discussed here. Occupational asthma is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34824?source=see_link\">",
"     \"Occupational asthma: Definitions, epidemiology, causes, and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36089?source=see_link\">",
"     \"Occupational asthma: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38903?source=see_link\">",
"     \"Occupational asthma: Pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occupational allergic diseases are common and appear to be increasing, with an estimated worldwide prevalence of 5 to 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The prevalence of OR specifically is not precisely known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Issues in estimating prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevalence estimates of OR vary with the methods used for diagnosis (questionnaire, objective evaluation), the occupation studied, and the geographic area in question (which may have distinctive industries).",
"   </p>",
"   <p>",
"    The following factors complicate prevalence studies of OR:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rhinitis from all causes is a common disorder in the general population. Studies should include a control group of workers from the same population, who are employed in a different and low-risk occupation.",
"     </li>",
"     <li>",
"      Questionnaires, without objective testing for sensitization to occupational allergens or direct nasal challenges with the suspect agent, are less reliable because there are numerous causes of rhinitis.",
"     </li>",
"     <li>",
"      The most accurate studies confirm the patient's reactivity using direct nasal challenges and an objective means of quantitating the patient's response. Nasal challenge procedures are reviewed below. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Direct nasal challenge'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following studies estimated OR in specific occupations and illustrate the importance of confirmatory nasal challenge:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laboratory employees who work with animals are one of the groups most commonly affected with occupational rhinitis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      asthma. More than 40 percent of 156 workers reported rhinitis symptoms in one study, with 51 percent demonstrating skin test reactivity to laboratory animals [",
"      <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/4\">",
"       4",
"      </a>",
"      ]. A positive nasal challenge was found in 15 percent of those with symptoms.",
"     </li>",
"     <li>",
"      A study of 1021 tobacco workers found that 27 percent reported rhinitis, compared to 18 percent of controls (hospital workers) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/5\">",
"       5",
"      </a>",
"      ]. A positive nasal challenge study was documented in 70 percent of those with symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bias also complicates prevalence studies. Underestimation may occur due to the healthy worker effect, which is a source of bias caused by the phenomenon that sicker individuals may choose work environments in which exposures are low or may be excluded from being hired. Similarly, already hired workers may seek transfer to less exposed jobs or leave work [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/6\">",
"     6",
"    </a>",
"    ]. This is the most common selection bias in occupational studies. Underestimation may also occur because of workers' reluctance to report symptoms for fear of losing employment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     High-risk occupations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of OR in various occupations was assessed in a study which analyzed 1244 incident cases of occupational rhinitis reported from 1986 to 1991 to the Finnish Register of Occupational Diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/7\">",
"     7",
"    </a>",
"    ]. The greatest risk of occupational rhinitis was among furriers, followed by bakers, livestock breeders, food processing workers, veterinarians, farmers, assemblers of electrical, electronic, and telecommunication products, and boat builders. A later study identified medical workers and pharmacy professionals as additional high-risk groups [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/8\">",
"     8",
"    </a>",
"    ]. In contrast, office workers are at low-risk for OR.",
"   </p>",
"   <p>",
"    As mentioned previously, laboratory employees working with small animals are one of the highest risk groups in the United States, the United Kingdom, and several European countries [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/9\">",
"     9",
"    </a>",
"    ]. Studies have reported that the prevalence of laboratory animal allergy is 10 percent to 23 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/9-11\">",
"     9-11",
"    </a>",
"    ] and that the incidence rate is 1.56 per 1000 workers for occupational asthma and 2.54 per 1000 workers for occupational rhinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/12\">",
"     12",
"    </a>",
"    ]. A study suggests that indirect exposure may be as risky for sensitization to laboratory animal antigens as direct exposure. Also, even nonsensitized workers may still be at risk for occupational rhinitis as aerosolized endotoxin from animals has been shown to cause symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following preexistent symptoms and conditions have been implicated as risk factors for the development of OR:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Other atopic disorders, particularly allergic rhinitis and asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/4,14,15\">",
"       4,14,15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A high level of total IgE (&gt;150",
"      <span class=\"nowrap\">",
"       kIU/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Exposure to known respiratory irritants in the workplace, resulting in increased nasal hyperreactivity [",
"      <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Nonspecific nasal symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Respiratory symptoms upon exposure to dust or strong odors [",
"      <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Smoking has not been established as a risk factor for OR, although it does increase the risk of developing some forms of occupational asthma. The relationship between duration of exposure to an occupational agent and the development of OR has not been extensively studied. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34824?source=see_link\">",
"     \"Occupational asthma: Definitions, epidemiology, causes, and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;OR can arise from several different mechanisms. A review of nasal physiology is important in understanding the mechanisms responsible for occupational rhinitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Nasal physiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nasal mucus membrane can respond to noxious stimuli in various ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congestion resulting from vasodilatation, increased vascular permeability, and sinusoidal pooling in the vascular beds draining the sinus tissues",
"     </li>",
"     <li>",
"      Pruritus and sneezing due to sensory nerve stimulation",
"     </li>",
"     <li>",
"      The production of secretions resulting from glandular stimulation and increased vascular permeability",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nasal challenge has provided an excellent model for quantifying responses and for obtaining insights into nasal physiology. The nose can be challenged with allergens, mediators, or irritants. The response can be quantified by symptom scores, nasal airway resistance, and the study of secretions. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Direct nasal challenge'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Specific measurements of secretions include amount, composition, and content of various regulatory molecules, proteins, enzymes, and cells. Some of the components of nasal secretions that have been studied are prostaglandin D2 (PGD2), toxoid-antitoxoid mixture esterase (TAMe), kinins, albumin, immunoglobulins, lactoferrin, tryptase, and major basic protein.",
"   </p>",
"   <p>",
"    An early response is universal in atopic individuals after nasal challenge with an allergen to which the patient is sensitized. Sneezing, nasal congestion, and an increase in secretions develop within minutes. This early reaction is followed in four to six hours by a late response similar to that seen in the lung after bronchial challenge. The late response includes a cellular influx that can be demonstrated in nasal lavage fluid. Total cells increase, as do epithelial cells, eosinophils, neutrophils, and mononuclear cells. Nasal lavage fluid obtained within 11 hours of the challenge shows increased levels of histamine, TAMe, PGD2, and kinins [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/18\">",
"     18",
"    </a>",
"    ]. PGD2, a mediator found in mast cells but not in basophils, is not increased, suggesting that basophils are involved in the late phase response. Just as in the lung, the late phase reaction in the nose is associated with a heightened response to allergen and to nonspecific agents such as histamine [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Classification and mechanisms of OR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following classification system for occupational rhinitis has been suggested (",
"    <a class=\"graphic graphic_table graphicRef72564 \" href=\"UTD.htm?24/34/25132\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Annoyance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Annoyance OR is a purely subjective condition that occurs in individuals with a heightened olfactory awareness to substances, such as department store or supermarket employees who become symptomatic upon exposure to perfumes or detergents, respectively. Nasal mucosal inflammation is not evident. Annoyance OR is a negative psychological state, at times in conjunction with transient physical symptoms, related to the perception of offensive air quality due to strong odors. The likelihood of developing annoyance reactions is increased by nasal polyposis, sinusitis, tobacco use, and overuse of over-the-counter nasal decongestants or illicit drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/16\">",
"     16",
"    </a>",
"    ]. The mechanism has not been demonstrated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Irritant-induced",
"    </span>",
"    &nbsp;&mdash;&nbsp;Irritant-induced or irritational OR is defined as inflammation of the nasal mucosa that has no immunologic or allergic basis. Exposure to substances such as cigarette smoke, formalin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    results in the release of substance P, a sensory transmitter that in turn triggers a neurogenic inflammatory response. This type of occupational rhinitis is seen in workers in enclosed environments exposed to materials such as paints, talc, coal dust, air pollutants, or cold air (",
"    <a class=\"graphic graphic_table graphicRef72564 \" href=\"UTD.htm?24/34/25132\">",
"     table 1",
"    </a>",
"    ). Cleaners and janitors can develop irritational OR in response to cleaning products [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Corrosive",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corrosive OR results from exposure to a high concentration of irritating and soluble chemical gases, causing sufficient nasal inflammation that the mucosa may break down and ulcerate, similar to a chemical burn. Common culprits include substances with high water solubility and chemical reactivity, such as chlorine, sulphur dioxide, ammonia, and formaldehyde (",
"    <a class=\"graphic graphic_table graphicRef72564 \" href=\"UTD.htm?24/34/25132\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/23\">",
"     23",
"    </a>",
"    ]. Corrosive OR can lead to permanent changes in physiologic functions of the nose, such as loss of olfaction. The entity \"reactive upper-airways dysfunction syndrome\" (RUDS) has been described after a single exposure to strong chemicals, and is modeled on reactive airways dysfunction syndrome (RADS) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/28/8650?source=see_link\">",
"     \"Reactive airways dysfunction syndrome and irritant-induced asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Allergic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic or immunologic OR is mediated by IgE, with resultant early and late nasal secretions. High molecular weight allergens or low molecular weight allergens bound to proteins can elicit an allergic response. Many low molecular weight agents may not be immunogenic by themselves, but are excellent haptens and can combine with other tissue proteins such as human serum albumin in the respiratory tract. The resultant hapten-protein conjugate acts as a potent immunogen [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/24\">",
"     24",
"    </a>",
"    ]. These mechanisms are identical to those underlying immunologic forms of occupational asthma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38903?source=see_link\">",
"     \"Occupational asthma: Pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examples of substances known to cause allergic OR include rodent allergens (laboratory workers), latex (health care workers), guar gum (carpet workers), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/26/8614?source=see_link\">",
"     psyllium",
"    </a>",
"    used in laxatives (nurses) (",
"    <a class=\"graphic graphic_table graphicRef72564 \" href=\"UTD.htm?24/34/25132\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Immunologic/allergic",
"    </span>",
"    OR is often associated with ocular symptoms, such as ocular itching, excessive tearing, redness, and swelling of the eyelids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34856?source=see_link\">",
"     \"Allergic conjunctivitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Levels of exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with OR are not necessarily exposed to levels of the causative agent that are considered unsafe by industry standards [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/25\">",
"     25",
"    </a>",
"    ]. A study of customs officers found that changes in nasal cytology were evident in those exposed to diesel exhaust emissions, although the levels were well within the permitted range [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with",
"    <span class=\"nowrap\">",
"     immunologic/allergic",
"    </span>",
"    OR, even minute amounts of allergen can trigger symptoms in susceptible patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms of occupational rhinitis are nasal congestion, sneezing, nasal pruritus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased nasal secretions in association with exposure to the workplace. Since occupational rhinitis can be associated with a late reaction, symptoms may not appear until several hours after leaving the workplace. Late-onset symptoms in the absence of immediate symptoms is uncommon, although it has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/27\">",
"     27",
"    </a>",
"    ]. In some forms of OR, there may be associated ocular or pulmonary signs and symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Timing of symptom onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms of OR usually appear within the first one to three years of employment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/14,25,28,29\">",
"     14,25,28,29",
"    </a>",
"    ]. However, the latency period between exposure and symptom onset may differ among occupations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following four steps are suggested in the evaluation of occupational rhinitis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History and physical examination",
"     </li>",
"     <li>",
"      Site visit",
"     </li>",
"     <li>",
"      In cases of suspected",
"      <span class=\"nowrap\">",
"       immunologic/allergic",
"      </span>",
"      OR: skin testing or in vitro testing for allergen-specific IgE to the suspect agent (if possible) and to a standard panel of aeroallergens",
"     </li>",
"     <li>",
"      Nasal challenge",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A comprehensive occupational history should contain questions pertaining to the following [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Onset of symptoms at work",
"     </li>",
"     <li>",
"      Improvement on weekends or vacations",
"     </li>",
"     <li>",
"      Recurrence of symptoms on reexposure",
"     </li>",
"     <li>",
"      Exposure to cold air, ozone (eg, pulp mill and bleachery workers), pollution, tobacco smoke, animals, and dusts",
"     </li>",
"     <li>",
"      Similar symptoms in co-workers",
"     </li>",
"     <li>",
"      Duration working at current job",
"     </li>",
"     <li>",
"      Adequacy of ventilation",
"     </li>",
"     <li>",
"      Compliance with wearing gloves, masks, protective clothing",
"     </li>",
"     <li>",
"      History of accidents or spills",
"     </li>",
"     <li>",
"      Safety monitoring",
"     </li>",
"     <li>",
"      Review of Material Safety Data Sheets",
"     </li>",
"     <li>",
"      Personal or family history of atopy",
"     </li>",
"     <li>",
"      Coexisting symptoms such as bronchitis, dermatitis, conjunctivitis, or anosmia",
"     </li>",
"     <li>",
"      Tobacco use",
"     </li>",
"     <li>",
"      Previous employment",
"     </li>",
"     <li>",
"      Intranasal medications (eg, topical decongestants) or illicit drugs (eg, cocaine)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination during the time of active rhinitis reveals swollen nasal turbinates and evidence of increased secretions. Nasal findings may be minimal in patients with annoyance OR, whereas corrosive OR may reveal ulcerated and hemorrhagic mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Exclude infectious rhinosinusitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infectious rhinosinusitis should be excluded, because it is such a common condition. Symptoms of infectious rhinosinusitis include persistent nasal blockage and purulent postnasal drainage. OR may predispose to rhinosinusitis by causing inflammatory swelling of the nasal mucosa, which leads to blockage of the ostia, decreased aeration, and impaired drainage from the sinuses. Acute and chronic forms of rhinosinusitis are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39688?source=see_link\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2297?source=see_link\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Site visit",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scheduling a site visit to the workplace is helpful in determining the exact cause of OR. A site visit can provide the clinician with an opportunity to confirm and add to the previously obtained history by observing the patient as he or she performs the work. The site visit is also critical for determining if any changes can be made in the work environment to reduce the patient's ongoing exposure.",
"   </p>",
"   <p>",
"    In the United States, the Occupational Safety and Health Administration (OSHA) requires employers to keep on site records detailing the ingredients and possible health effects of materials and substances to which workers are exposed. This information is available in Material Safety Data Sheets, which should be reviewed during the site visit. These sheets can be helpful in establishing a causal agent in OR.",
"   </p>",
"   <p>",
"    A toxicologist can be called in to sample air quality if there is a question of inadequate ventilation. However, patients may develop OR (especially allergic OR) from exposure to \"safe\" amounts of agents, as previously mentioned. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Levels of exposure'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Testing for allergen-specific IgE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergy skin testing and in vitro IgE immunoassays (commonly called RAST tests) are methods for detecting allergen-specific IgE. These tests document sensitization to the allergen (ie, the presence of allergen-specific IgE), although not all sensitized patients develop symptoms upon exposure. Thus, direct nasal challenge remains the gold standard for the diagnosis of OR.",
"   </p>",
"   <p>",
"    Allergy skin testing is considered a safe procedure, although there is some risk for a generalized allergic reaction (ie, anaphylaxis) in highly sensitive patients. Therefore, skin testing should be performed by allergy specialists, who have training in the rapid recognition and treatment of possible reactions. In contrast, IgE immunoassays can be ordered by any clinician, although this form of testing may be less sensitive than skin testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22362?source=see_link\">",
"     \"Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Testing for allergen-specific IgE is appropriate if both of the following are true:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The OR is believed to be due to an IgE-mediated mechanism (ie, immunologic OR)",
"     </li>",
"     <li>",
"      If there is validated testing extract available for the allergen in question, such as animal danders [",
"      <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/30\">",
"       30",
"      </a>",
"      ], dust mite, latex, or mold. Unfortunately, approved extracts do not exist for many other occupational allergens.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If a validated extract is not available, then testing with improvised solutions of the suspect allergen is generally not recommended because irritating substances can cause false positive results. In addition, false negative results may occur with low-molecular weight allergens, which may need to be conjugated with serum albumin to elicit a positive response [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, skin testing to common aeroallergens may provide useful information about the general atopic status of the patient, as patients with allergic rhinitis to inhaled allergens are at increased risk for OR. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the community, the diagnosis of occupational rhinitis is most often based upon history, suggestive clinical signs and symptoms, and (if feasible) observation of the patient's symptoms during a site visit. At some centers, the patient is given a diary and instructed to record symptoms several times daily during the work week, on weekends, and during any prolonged absences from the workplace, although this is a purely subjective measurement.",
"   </p>",
"   <p>",
"    For research purposes and at specialty centers, the diagnosis of OR should be established with direct nasal challenge, using a standardized system for objectively quantitating symptoms. Direct nasal challenge techniques will be discussed in this section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Direct nasal challenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct nasal challenge is the gold standard for the diagnosis of OR. It can be performed either at the workplace, or under controlled circumstances in the office or laboratory. Responses may be quantified either by symptom score or by rhinomanometry, a technique that measures changes in nasal airway resistance. As mentioned previously, these techniques require special equipment and training, and are not practical for most community clinicians or allergy specialists.",
"   </p>",
"   <p>",
"    A position paper published by the European Academy of Allergy and Clinical Immunology (EAACI) suggests that workplace challenges be considered in the following settings [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No sensitizing agent has been firmly identified at work, or",
"     </li>",
"     <li>",
"      Multiple potentially sensitizing agents are present at the workplace, or",
"     </li>",
"     <li>",
"      Conditions of exposure at work cannot be duplicated in the laboratory, or",
"     </li>",
"     <li>",
"      Nasal provocation tests in the lab are not feasible for unavailability of equipped facilities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During the challenge, the worker performs his or her usual tasks and nasal response is gauged before, during, and after a typical shift. Patients act as their own controls by comparing workday symptoms to non-workday symptoms. This may be done several times to ascertain sufficient reproducibility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Rhinomanometry techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three common rhinomanometry techniques: anterior, posterior, and acoustic:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anterior rhinomanometry calculates nasal airway resistance from the relationship between flow rate and pressure. Commercially available anterior rhinomanometers measure airflow through one nostril by means of a closely fitting face-mask, whereas the other nostril is sealed with a small tube to measure nasopharyngeal pressure. The technique is easy to perform, requires little patient cooperation, and is especially convenient for nasal provocation. The disadvantages include distortion of the nasal valves by the probe, reflex changes resulting from tactile sensations, and sensitivity of the measurement to nasal cycling (ie, a normal phenomenon in which nasal turbinates on alternate sides of the nose swell at intervals of two to five hours) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. Normal nasal function and reflexes are reviewed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/44/16072?source=see_link\">",
"       \"Etiologies of nasal symptoms: An overview\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30999?source=see_link&amp;anchor=H14#H14\">",
"       \"An overview of rhinitis\", section on 'Normal nasal reflexes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Posterior rhinomanometry employs a face-mask fitted with a pneumotachometer, and monitors airflow through both nostrils simultaneously, as well as anterior nasal pressure. Posterior rhinomanometry avoids the disadvantages of artifacts from nasal instrumentation and nasal cycling, although the equipment is expensive and the procedure is difficult to perform on some patients. Approximately 20 percent of healthy individuals do not have sufficient palatal control to permit accurate pressure flow recordings to be obtained [",
"      <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Acoustic rhinomanometry is a simple, easily reproducible, and less invasive procedure, in which sound waves are introduced into the nasal cavity and a computer quantifies the reflected waves [",
"      <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. Of the three techniques, acoustic rhinomanometry is the most practical and least invasive.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of occupational rhinitis includes avoidance of the causative agent and pharmacotherapy with intranasal glucocorticoid sprays",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nonsedating antihistamines. In the United States, OR is not a reportable condition, in contrast to occupational asthma.",
"   </p>",
"   <p>",
"    Patients with severe symptoms that are not relieved by the measures described below, combined with pharmacotherapy, may need to consider a change in employment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Avoidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of OR begins with eliminating or minimizing exposure to the causative agent. In our experience, effective avoidance usually results in resolution of symptoms. In a prospective study, workers with bell pepper-occupational rhinitis who changed jobs reported significant improvement in symptoms and quality of life, even in those with pre-existing rhinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exposure may be reduced in a number of ways, including [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Substitution of the causative agent with an alternative material",
"     </li>",
"     <li>",
"      Consistent use of protective equipment such as a mask",
"     </li>",
"     <li>",
"      Improved ventilation or containment of the causative agent",
"     </li>",
"     <li>",
"      Reduced exposure times to the causative agent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Following these measures could well make it possible for the worker to maintain employment.",
"   </p>",
"   <p>",
"    The natural history of OR has not been extensively studied, nor has the impact of ongoing exposure to causative agents. There is a lack of evidence that OR progresses to more extensive respiratory involvement. However, it is not known if some patients develop rhinitis initially in response to occupational agents, but then become sensitive to other triggers and develop persistent symptoms despite avoidance of the initial culprit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Corrosive OR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Avoidance is the sole treatment for corrosive rhinitis, and the worker must be adequately protected from corrosive materials. Medications should not be used to reduce the clinical manifestations of this condition because the patient's awareness of symptoms is important to avoid mucosal injury. Recovery rates and sequelae from this form of nasal injury have not been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacotherapy can be helpful for annoyance, irritational, and allergic forms of OR, although there are no randomized trials or even large series evaluating pharmacotherapy for OR specifically. Recommendations for management are extrapolated from the literature on allergic rhinitis and, in our experience, are equally helpful for allergic OR. However, the response of annoyance and irritational OR to these therapies has not been reported.",
"   </p>",
"   <p>",
"    Patients should be counseled that medications are only palliative, rather than curative, and efforts to reduce exposure are primary. Ideally, pharmacotherapy should be continued until the patient can control symptoms by avoiding exposure to the offending agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Intranasal glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical glucocorticoid nasal sprays are most effective when taken regularly, although they can be used on an as-needed basis. Preparations with once-daily dosing are convenient and can help optimize compliance. These include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    propionate,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36080?source=see_link\">",
"     mometasone",
"    </a>",
"    furoate, or fluticasone furoate. Most intranasal glucocorticoids are used at a dose of 1 to 2 puffs in each nostril once or twice a day. The optimal use of these medications is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=see_link\">",
"     \"Pharmacotherapy of allergic rhinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Antihistamines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over-the-counter or prescription nonsedating antihistamines are also helpful for managing annoyance, irritational, and immunologic OR. Antihistamines are less effective for allergic rhinitis than topical glucocorticoid nasal sprays, although some patients prefer oral medications. When the patient's symptoms are episodic and predictable, prophylactic use before exposure is usually sufficient. When symptoms are frequent or unpredictable, regular use of an antihistamine may be necessary.",
"   </p>",
"   <p>",
"    We avoid sedating first generation antihistamines (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/52/24390?source=see_link\">",
"     chlorpheniramine",
"    </a>",
"    , astemizole, and others), since the goal of treatment is to increase alertness and job performance. The second generation, less-sedating antihistamines include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7799?source=see_link\">",
"     loratadine",
"    </a>",
"    (10 mg once daily),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12934?source=see_link\">",
"     desloratadine",
"    </a>",
"    (5 mg once daily),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/33/35350?source=see_link\">",
"     fexofenadine",
"    </a>",
"    (180 mg once daily), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"     cetirizine",
"    </a>",
"    (10 mg once daily), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/45/44757?source=see_link\">",
"     levocetirizine",
"    </a>",
"    (2.5 or 5 mg once daily). The choice of agent is often based on trial and error, side effect profile, cost to the patient, and availability. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=see_link\">",
"     \"Pharmacotherapy of allergic rhinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The topical antihistamine nasal spray,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/15/33008?source=see_link\">",
"     azelastine",
"    </a>",
"    , may also be helpful. Azelastine has a rapid onset of action (less than 15 minutes) and can be administered \"on demand\" for patients with episodic and unpredictable exposures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=see_link\">",
"     \"Pharmacotherapy of allergic rhinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other adjunctive therapies that may be helpful to some patients include topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide and leukotriene modifiers [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/38\">",
"     38",
"    </a>",
"    ]. Nasal irrigation with saline to wash allergens and irritants from the nose may be performed when the patient is done with work for the day. Again, these interventions have not been studied specifically for OR, although they have been shown to help various other types of rhinitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=see_link\">",
"     \"Pharmacotherapy of allergic rhinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with accompanying ocular symptoms, ophthalmic solutions of",
"    <span class=\"nowrap\">",
"     antihistamines/mast",
"    </span>",
"    cell stabilizers may provide as needed prophylactic or symptomatic treatment of accompanying conjunctivitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34856?source=see_link\">",
"     \"Allergic conjunctivitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Allergen immunotherapy is not currently recommended for the majority of patients with occupational rhinitis, for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergen immunotherapy has no role in the management of rhinitis caused by irritative or corrosive substances.",
"     </li>",
"     <li>",
"      Therapeutic extracts have not been produced for most occupational allergens, and in some cases, may not be safe.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In cases where appropriate allergens are available, such as veterinarians with OR caused by cat or dog allergens, the efficacy of allergen immunotherapy in the setting of ongoing intense exposure has not been evaluated. It is the authors&rsquo; anecdotal experience that cat or dog immunotherapy in small animal veterinarians is useful, particularly if the patient also limits non-work-related exposure by not keeping such pets in the home.",
"   </p>",
"   <p>",
"    Preliminary studies have described immunotherapy with certain occupational allergens that are not easily avoided (eg, natural rubber latex for health care workers) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/39-41\">",
"     39-41",
"    </a>",
"    ], although the safety and efficacy of this approach require further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;OR is sometimes described as an early form of occupational respiratory disease that may progress to asthma in some patients who continue to be exposed to the causative agent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/7,42\">",
"     7,42",
"    </a>",
"    ]. However, firm evidence for this progression is lacking, and many patients appear to have stable OR over a period of years. This is in contrast to occupational asthma, which usually worsens with continued exposure.",
"   </p>",
"   <p>",
"    We advise our patients to protect themselves as much as possible from ongoing exposure, and to consider changing work environments if their symptoms appear to be worsening despite avoidance measures. A study among OR patients showed continuous occupational exposure decreased quality of life years after the diagnosis. The authors concluded that to restore the well being of patients with OR, medication alone was not sufficient; reduction or cessation of exposure was necessary. In contrast, quality of life of OR patients no longer exposed was similar to healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening applicants for jobs in which there is a risk of workplace sensitization has been proposed as a means of preventing allergic OR. A study of 110 laboratory animal workers reported that the combination of atopy and total IgE level &ge;100",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    could be used as a pre-employment screen to predict which workers would develop occupational allergy. The study estimated that such screening might be able to reduce occupational sensitization by up to 45 to 50 percent, with less than 10 percent false-positive predictions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/44\">",
"     44",
"    </a>",
"    ]. However, the social, financial, and legal implications of such screening necessitate careful consideration, and we believe that these measures require further study before they are applied clinically.",
"   </p>",
"   <p>",
"    Nonatopic individuals can also develop OR, and screening for atopy does not identify at risk subjects in this group. In a study of applicants for laboratory jobs involving rat exposure, applicants were screened with a panel of common inhalant allergens to identify atopic individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/45\">",
"     45",
"    </a>",
"    ]. Of the 41 workers who were initially atopic by history and skin testing, 23 percent went on to develop OR. However, a significant number of the workers who developed rat allergies were not initially atopic.",
"   </p>",
"   <p>",
"    A more general approach to prevention, which applies to all workers and all forms of OR, is to institute environmental control measures proactively. It is important to recognize and identify potential sources of offending allergens and then minimize the worker's exposure to them as much as possible. This may be as simple as providing adequate ventilation.",
"   </p>",
"   <p>",
"    An example of the effectiveness of environmental control measures was seen in the detergent industry. The Bacillus subtilis enzyme added to household detergents caused a significant amount of upper and lower respiratory tract allergy in workers. By instituting a number of precautions during the production process, the incidence of occupational respiratory disease was greatly decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?7/48/7945/abstract/46\">",
"     46",
"    </a>",
"    ]. These precautions included enclosing previously open operations, supplying heavily exposed workers with space suits with air supply, providing disposable gloves and uniforms, providing masks with cartridge filters to workers with low exposure, monitoring the air by measuring enzyme concentrations, and performing spot checks on workers. These spot checks consisted of a history and physical examination, chest radiographs, pulmonary function testing, skin testing, and serologic testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occupational rhinitis (OR) has been defined as episodic, work-related occurrence of sneezing, nasal discharge, nasal pruritus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nasal obstruction. OR often coexists with occupational asthma, although significant numbers of patients develop just one of these conditions. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Clinical features and diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall prevalence of OR is unknown and accurate identification is complicated by the high prevalence of rhinitis in general. High-risk professions include laboratory workers, food processing workers, veterinarians, farmers and livestock workers, and assemblers of electronic and telecommunication products. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      OR may develop in response to respiratory irritants, corrosive gases, or allergens. It may be IgE-mediated of non IgE-mediated. A classification system delineates four subtypes: annoyance, irritational, corrosive, and",
"      <span class=\"nowrap\">",
"       immunologic/allergic",
"      </span>",
"      (",
"      <a class=\"graphic graphic_table graphicRef72564 \" href=\"UTD.htm?24/34/25132\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The symptoms of OR can develop within minutes to several hours after exposure. There may be associated ocular or pulmonary signs and symptoms. OR usually develops within the first few years of employment. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation of a patient suspected of having OR includes a detailed occupational history, physical examination, site visit, and in cases of suspected immunologic OR, skin testing or in vitro testing to common inhalant allergens. In a few situations, commercial extracts of occupational allergens are also available for testing, although we do not recommend testing with improvised extracts. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is usually made clinically, although for research purposes, symptoms should be elicited and confirmed by direct nasal challenge. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary therapy for all forms of OR is reduction or elimination of the patient's exposure to the causative agent. This is the only appropriate intervention for corrosive OR. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Avoidance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with other forms of OR (annoyance, irritational, and",
"      <span class=\"nowrap\">",
"       immunologic/allergic)",
"      </span>",
"      pharmacotherapy may be useful while avoidance measures are being put in place, or it may be needed on an ongoing basis. Medications may be used as needed for episodic and predictable exposures, or daily for regular or unpredictable exposures. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Pharmacotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients with",
"      <span class=\"nowrap\">",
"       immunologic/allergic",
"      </span>",
"      OR be treated with the same medications used for allergic rhinitis due to other allergens (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Pharmacotherapy is primarily based upon intranasal glucocorticoid sprays, nonsedating antihistamines, or both. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=see_link\">",
"       \"Pharmacotherapy of allergic rhinitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with annoyance and irritational forms of OR, we suggest therapeutic trials of the same agents (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Pharmacotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is currently minimal evidence that OR progresses to occupational asthma with continued exposure. Accordingly, in patients whose symptoms are controlled but who cannot eliminate exposure, we suggest AGAINST advising them that they must leave their jobs (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The development of screening parameters to identify those individuals at highest risk for allergic OR is an area of active investigation, but validated methods for clinical application are still lacking. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/1\">",
"      Moscato G, Vandenplas O, Van Wijk RG, et al. EAACI position paper on occupational rhinitis. Respir Res 2009; 10:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/2\">",
"      Slavin RG. Occupational rhinitis. Immunol Allergy Clin North Am 1992; 12:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/3\">",
"      Slavin RG. Update on occupational rhinitis and asthma. Allergy Asthma Proc 2010; 31:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/4\">",
"      Ruoppi P, Koistinen T, Susitaival P, et al. Frequency of allergic rhinitis to laboratory animals in university employees as confirmed by chamber challenges. Allergy 2004; 59:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/5\">",
"      Chloros D, Sichletidis L, Kyriazis G, et al. Respiratory effects in workers processing dried tobacco leaves. Allergol Immunopathol (Madr) 2004; 32:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/6\">",
"      Le Moual N, Kauffmann F, Eisen EA, Kennedy SM. The healthy worker effect in asthma: work may cause asthma, but asthma may also influence work. Am J Respir Crit Care Med 2008; 177:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/7\">",
"      Hyt&ouml;nen M, Kanerva L, Malmberg H, et al. The risk of occupational rhinitis. Int Arch Occup Environ Health 1997; 69:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/8\">",
"      Moscato G, Siracusa A. Rhinitis guidelines and implications for occupational rhinitis. Curr Opin Allergy Clin Immunol 2009; 9:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/9\">",
"      Lutsky II, Neuman I. Laboratory animal dander allergy: I. An occupational disease. Ann Allergy 1975; 35:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/10\">",
"      Aoyama K, Ueda A, Manda F, et al. Allergy to laboratory animals: an epidemiological study. Br J Ind Med 1992; 49:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/11\">",
"      Hollander A, Doekes G, Heederik D. Cat and dog allergy and total IgE as risk factors of laboratory animal allergy. J Allergy Clin Immunol 1996; 98:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/12\">",
"      Elliott L, Heederik D, Marshall S, et al. Incidence of allergy and allergy symptoms among workers exposed to laboratory animals. Occup Environ Med 2005; 62:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/13\">",
"      Jang JH, Kim DW, Kim SW, et al. Allergic rhinitis in laboratory animal workers and its risk factors. Ann Allergy Asthma Immunol 2009; 102:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/14\">",
"      Walusiak J, Hanke W, G&oacute;rski P, Paczyski C. Respiratory allergy in apprentice bakers: do occupational allergies follow the allergic march? Allergy 2004; 59:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/15\">",
"      Rodier F, Gautrin D, Ghezzo H, Malo JL. Incidence of occupational rhinoconjunctivitis and risk factors in animal-health apprentices. J Allergy Clin Immunol 2003; 112:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/16\">",
"      Puchner TC, Fink JN. Occupational Rhinitis. Immunol Allergy Clin North Am 2000; 20:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/17\">",
"      Gautrin D, Ghezzo H, Infante-Rivard C, Malo JL. Incidence and host determinants of work-related rhinoconjunctivitis in apprentice pastry-makers. Allergy 2002; 57:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/18\">",
"      Naclerio RM, Meier HL, Kagey-Sobotka A, et al. Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis 1983; 128:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/19\">",
"      Naclerio RM, Proud D, Togias AG, et al. Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med 1985; 313:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/20\">",
"      Bardana EJ Jr. Occupational asthma and related respiratory disorders. Dis Mon 1995; 41:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/21\">",
"      de F&aacute;tima Ma&ccedil;&atilde;ira E, Algranti E, Medina Coeli Mendon&ccedil;a E, Ant&ocirc;nio Bussacos M. Rhinitis and asthma symptoms in non-domestic cleaners from the Sao Paulo metropolitan area, Brazil. Occup Environ Med 2007; 64:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/22\">",
"      Radon K, Gerhardinger U, Schulze A, et al. Occupation and adult onset of rhinitis in the general population. Occup Environ Med 2008; 65:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/23\">",
"      Hellgren J, Tor&eacute;n K. Nonallergic occupational rhinitis. Clin Allergy Immunol 2007; 19:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/24\">",
"      Slavin RG. Occupational rhinitis. Ann Allergy Asthma Immunol 2003; 90:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/25\">",
"      Cullinan P, Cook A, Nieuwenhuijsen MJ, et al. Allergen and dust exposure as determinants of work-related symptoms and sensitization in a cohort of flour-exposed workers; a case-control analysis. Ann Occup Hyg 2001; 45:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/26\">",
"      Gl&uuml;ck U, Sch&uuml;tz R, Gebbers JO. Cytopathology of the nasal mucosa in chronic exposure to diesel engine emission: a five-year survey of Swiss customs officers. Environ Health Perspect 2003; 111:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/27\">",
"      Blainey AD, Graham VA, Phillips MJ, Davies RJ. Respiratory tract reactions to western red cedar. Hum Toxicol 1981; 1:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/28\">",
"      Cullinan P, Cook A, Gordon S, et al. Allergen exposure, atopy and smoking as determinants of allergy to rats in a cohort of laboratory employees. Eur Respir J 1999; 13:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/29\">",
"      Gautrin D, Ghezzo H, Infante-Rivard C, Malo JL. Natural history of sensitization, symptoms and occupational diseases in apprentices exposed to laboratory animals. Eur Respir J 2001; 17:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/30\">",
"      Sharma HP, Wood RA, Bravo AR, Matsui EC. A comparison of skin prick tests, intradermal skin tests, and specific IgE in the diagnosis of mouse allergy. J Allergy Clin Immunol 2008; 121:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/31\">",
"      Schumacher MJ. Rhinomanometry. J Allergy Clin Immunol 1989; 83:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/32\">",
"      Baraniuk JN, Kim D. Nasonasal reflexes, the nasal cycle, and sneeze. Curr Allergy Asthma Rep 2007; 7:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/33\">",
"      Hytonen ML, Sala EL, Malmberg HO, Nordman H. Acoustic rhinomanometry in the diagnosis of occupational rhinitis. Am J Rhinol 1996; 10:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/34\">",
"      Castano R, Th&eacute;riault G, Gautrin D, et al. Reproducibility of acoustic rhinometry in the investigation of occupational rhinitis. Am J Rhinol 2007; 21:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/35\">",
"      Gerth van Wijk R, Patiwael JA, de Jong NW, et al. Occupational rhinitis in bell pepper greenhouse workers: determinants of leaving work and the effects of subsequent allergen avoidance on health-related quality of life. Allergy 2011; 66:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/36\">",
"      Gautrin D, Desrosiers M, Castano R. Occupational rhinitis. Curr Opin Allergy Clin Immunol 2006; 6:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/37\">",
"      Hellgren J, Karlsson G, Tor&eacute;n K. The dilemma of occupational rhinitis: management options. Am J Respir Med 2003; 2:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/38\">",
"      Puchner TC, Fink JN. Occupational Rhinitis. Immunol Allergy Clin North Am 2000; 20:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/39\">",
"      Sastre J, Fern&aacute;ndez-Nieto M, Rico P, et al. Specific immunotherapy with a standardized latex extract in allergic workers: a double-blind, placebo-controlled study. J Allergy Clin Immunol 2003; 111:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/40\">",
"      Nettis E, Colanardi MC, Soccio AL, et al. Double-blind, placebo-controlled study of sublingual immunotherapy in patients with latex-induced urticaria: a 12-month study. Br J Dermatol 2007; 156:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/41\">",
"      Hansen I, H&ouml;rmann K, Klimek L. [Specific immunotherapy in inhalative allergy to rat epithelium]. Laryngorhinootologie 2004; 83:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/42\">",
"      Settipane RJ, Hagy GW, Settipane GA. Long-term risk factors for developing asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Proc 1994; 15:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/43\">",
"      Airaksinen LK, Luukkonen RA, Lindstr&ouml;m I, et al. Long-term exposure and health-related quality of life among patients with occupational rhinitis. J Occup Environ Med 2009; 51:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/44\">",
"      Krop EJ, Heederik DJ, Lutter R, et al. Associations between pre-employment immunologic and airway mucosal factors and the development of occupational allergy. J Allergy Clin Immunol 2009; 123:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/45\">",
"      Platts-Mills TA, Longbottom J, Edwards J, et al. Occupational asthma and rhinitis related to laboratory rats: serum IgG and IgE antibodies to the rat urinary allergen. J Allergy Clin Immunol 1987; 79:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/48/7945/abstract/46\">",
"      Slavin RG, Lewis CR. Sensitivity to enzyme additives in laundry detergent workers. J Allergy Clin Immunol 1971; 48:262.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7529 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-190.92.87.115-3AD7EB5AF7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_48_7945=[""].join("\n");
var outline_f7_48_7945=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Issues in estimating prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      High-risk occupations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Nasal physiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Classification and mechanisms of OR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Annoyance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Irritant-induced",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Corrosive",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Allergic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Levels of exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Timing of symptom onset",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Exclude infectious rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Site visit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Testing for allergen-specific IgE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Direct nasal challenge",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Rhinomanometry techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Avoidance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Corrosive OR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Intranasal glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Antihistamines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Other therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/7529\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/7529|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/34/25132\" title=\"table 1\">",
"      Types of occupational rhinitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39688?source=related_link\">",
"      Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2297?source=related_link\">",
"      Acute sinusitis and rhinosinusitis in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34856?source=related_link\">",
"      Allergic conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22362?source=related_link\">",
"      Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30999?source=related_link\">",
"      An overview of rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/44/16072?source=related_link\">",
"      Etiologies of nasal symptoms: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36089?source=related_link\">",
"      Occupational asthma: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34824?source=related_link\">",
"      Occupational asthma: Definitions, epidemiology, causes, and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38903?source=related_link\">",
"      Occupational asthma: Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=related_link\">",
"      Pharmacotherapy of allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/28/8650?source=related_link\">",
"      Reactive airways dysfunction syndrome and irritant-induced asthma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_48_7946="Ibuprofen: Pediatric drug information";
var content_f7_48_7946=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ibuprofen: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"    see \"Ibuprofen: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"    see \"Ibuprofen: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F181456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Addaprin [OTC];",
"     </li>",
"     <li>",
"      Advil&reg; Children's [OTC];",
"     </li>",
"     <li>",
"      Advil&reg; Infants' [OTC];",
"     </li>",
"     <li>",
"      Advil&reg; Migraine [OTC];",
"     </li>",
"     <li>",
"      Advil&reg; [OTC];",
"     </li>",
"     <li>",
"      Caldolor&reg;;",
"     </li>",
"     <li>",
"      I-Prin [OTC];",
"     </li>",
"     <li>",
"      Ibu-200 [OTC];",
"     </li>",
"     <li>",
"      Ibu&reg;;",
"     </li>",
"     <li>",
"      Midol&reg; Cramps &amp; Body Aches [OTC];",
"     </li>",
"     <li>",
"      Motrin&reg; Children's [OTC];",
"     </li>",
"     <li>",
"      Motrin&reg; IB [OTC];",
"     </li>",
"     <li>",
"      Motrin&reg; Infants' [OTC];",
"     </li>",
"     <li>",
"      Motrin&reg; Junior [OTC];",
"     </li>",
"     <li>",
"      NeoProfen&reg;;",
"     </li>",
"     <li>",
"      Proprinal&reg; [OTC];",
"     </li>",
"     <li>",
"      TopCare&reg; Junior Strength [OTC];",
"     </li>",
"     <li>",
"      Ultraprin [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F181457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Advil&reg;;",
"     </li>",
"     <li>",
"      Advil&reg; Children's;",
"     </li>",
"     <li>",
"      Apo-Ibuprofen&reg;;",
"     </li>",
"     <li>",
"      Motrin&reg; (Children's);",
"     </li>",
"     <li>",
"      Motrin&reg; IB;",
"     </li>",
"     <li>",
"      Novo-Profen;",
"     </li>",
"     <li>",
"      Nu-Ibuprofen",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1053332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Non-narcotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antipyretic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nonsteroidal Anti-inflammatory Drug (NSAID), Oral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nonsteroidal Anti-inflammatory Drug (NSAID), Parenteral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Treatment of PDA: Ibuprofen lysine (NeoProfen&reg;): GA &le;32 weeks, birth weight: 500-1500 g: Initial dose: 10 mg/kg, followed by two doses of 5 mg/kg at 24 and 48 hours after the initial dose;",
"     <b>",
"      Note:",
"     </b>",
"     Use birth weight to calculate all doses. Hold second or third doses if urinary output is &lt;0.6 mL/kg/hour; may give when laboratory studies indicate renal function is back to normal. A second course of treatment, alternative pharmacologic therapy, or surgery may be needed if the ductus arteriosus fails to close or reopens following the initial course of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1053326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"      see \"Ibuprofen: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Adolescents &ge;17 years and Adults: Ibuprofen injection (Caldolor&reg;):",
"     <b>",
"      Note:",
"     </b>",
"     Patients should be well hydrated prior to administration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Analgesic: 400-800 mg every 6 hours as needed (maximum: 3.2 g/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Antipyretic: Initial: 400 mg, then 400 mg every 4-6 hours or 100-200 mg every 4 hours as needed (maximum: 3.2 g/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     To reduce the risk of adverse cardiovascular and GI effects, use the lowest effective dose for the shortest period of time:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Analgesic: 4-10 mg/kg/dose every 6-8 hours; maximum daily dose: 40 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Antipyretic: 6 months to 12 years: Temperature &lt;102.5&deg;F (39&deg;C): 5 mg/kg/dose; temperature &ge;102.5&deg;F: 10 mg/kg/dose; give every 6-8 hours; maximum daily dose: 40 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     JIA: 6 months to 12 years: Usual: 30-40 mg/kg/day in 3-4 divided doses; start at lower end of dosing range and titrate; patients with milder disease may be treated with 20 mg/kg/day; doses &gt;40 mg/kg/day may increase risk of serious adverse effects; doses &gt;50 mg/kg/day have not been studied and are not recommended; maximum dose: 2.4 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     OTC pediatric labeling (analgesic, antipyretic): 6 months to 11 years: 7.5 mg/kg/dose every 6-8 hours; maximum daily dose: 30 mg/kg",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:8em;text-align:justify;\">",
"     Manufacturer's recommendations: See table; use of weight to select dose is preferred; if weight is not available, then use age; doses may be repeated every 6-8 hours; maximum: 4 doses/day; treatment for &gt;10 days is not recommended unless directed by healthcare provider; treatment of sore throat for &gt;2 days or use in children &lt;3 years of age with sore throat is not recommended, unless directed by healthcare provider",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Ibuprofen Dosing",
"     </caption>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Weight",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (lbs)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Age",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dosage",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12-17",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6-11 mo",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         18-23",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12-23 mo",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         75",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         24-35",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         35-47",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4-5 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         150",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         48-59",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6-8 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         200",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         60-71",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         9-10 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         72-95",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         11 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         300",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;text-align:justify;\">",
"     Cystic fibrosis: Ibuprofen when taken chronically (for 4 years) in doses to achieve peak plasma concentrations of 50-100 mcg/mL has been shown to slow the progression of lung disease in mild cystic fibrosis patients &gt;5 years of age, and especially in patients who started therapy when &lt;13 years of age. Doses administered twice daily ranged from 16.2-31.6 mg/kg/dose with 90% of patients requiring 20-30 mg/kg/dose (mean dose: ~25 mg/kg/dose), but individual patient's dose requirements were not predictable. Patients did not take pancreatic enzymes nor eat for 2 hours after the dose (Konstan, 1995). In children with cystic fibrosis, an initial ibuprofen pharmacokinetic analysis is recommended using tablet doses of 20-30 mg/kg to optimize concentrations in the therapeutic range; blood sampling is recommended at 1, 2, and 3 hours postdose. A recent pharmacokinetic study in children with cystic fibrosis demonstrated that ibuprofen oral suspension also delivers therapeutic plasma concentrations; this study recommends using a 20 mg/kg dose of ibuprofen suspension for the initial pharmacokinetic analysis and obtaining blood samples at 30, 45, and 60 minutes postdose (Scott, 1999); further studies are needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Inflammatory disease: 400-800 mg/dose 3-4 times/day; maximum dose: 3.2 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pain/fever/dysmenorrhea: 200-400 mg/dose every 4-6 hours; maximum daily dose: 1.2 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     OTC labeling (analgesic, antipyretic): 200 mg every 4-6 hours as needed (maximum: 1200 mg/24 hours); treatment for &gt;10 days is not recommended unless directed by healthcare provider",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Severe hepatic impairment: Avoid use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Advanced renal disease: Use is not recommended",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F181430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advil&reg;: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Motrin&reg; IB: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Motrin&reg; Junior: 100 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, liquid filled, oral: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advil&reg;: 200 mg [contains potassium 20 mg/capsule; solubilized ibuprofen]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advil&reg; Migraine: 200 mg [contains potassium 20 mg/capsule; solubilized ibuprofen]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral: 200 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gelcap, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advil&reg;: 200 mg [contains coconut oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Caldolor&reg;: 100 mg/mL (4 mL, 8 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as lysine [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NeoProfen&reg;: 17.1 mg/mL (2 mL) [equivalent to ibuprofen base 10 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral: 100 mg/5 mL (5 mL, 10 mL, 120 mL, 240 mL, 480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advil&reg; Children's: 100 mg/5 mL (120 mL) [contains propylene glycol, sodium 10 mg/5 mL, sodium benzoate; blue raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advil&reg; Children's: 100 mg/5 mL (120 mL) [contains propylene glycol, sodium 3 mg/5 mL, sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advil&reg; Children's: 100 mg/5 mL (120 mL) [contains sodium 3 mg/5 mL, sodium benzoate; fruit flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Motrin&reg; Children's: 100 mg/5 mL (120 mL) [dye free, ethanol free; contains sodium 2 mg/5 mL, sodium benzoate; berry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Motrin&reg; Children's: 100 mg/5 mL (60 mL, 120 mL) [ethanol free; contains sodium 2 mg/5 mL, sodium benzoate; berry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Motrin&reg; Children's: 100 mg/5 mL (120 mL) [ethanol free; contains sodium 2 mg/5 mL, sodium benzoate; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Motrin&reg; Children's: 100 mg/5 mL (120 mL) [ethanol free; contains sodium 2 mg/5 mL, sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Motrin&reg; Children's: 100 mg/5 mL (120 mL) [ethanol free; contains sodium 2 mg/5 mL, sodium benzoate; tropical punch flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral [concentrate/drops]: 40 mg/mL (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advil&reg; Infants': 40 mg/mL (15 mL) [contains sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advil&reg; Infants': 40 mg/mL (15 mL) [dye free; contains propylene glycol, sodium benzoate; white grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Motrin&reg; Infants': 40 mg/mL (15 mL) [dye free, ethanol free; contains sodium benzoate; berry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Motrin&reg; Infants': 40 mg/mL (15 mL) [ethanol free; contains sodium benzoate; berry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 200 mg, 400 mg, 600 mg, 800 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Addaprin: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advil&reg;: 200 mg [contains sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I-Prin: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ibu-200: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ibu&reg;: 400 mg, 600 mg, 800 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Midol&reg; Cramps &amp; Body Aches: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Motrin&reg; IB: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Proprinal&reg;: 200 mg [contains sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ultraprin: 200 mg [sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Motrin&reg; Junior: 100 mg [contains phenylalanine 2.8 mg/tablet; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Motrin&reg; Junior: 100 mg [contains phenylalanine 2.8 mg/tablet; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TopCare&reg; Junior Strength: 100 mg [scored; orange flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F181416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Caplet, liquid-filled capsule, softgel capsule, suspension, tablet",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088647.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088647.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1053337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Administer with food or milk to decrease GI upset; shake suspension well before use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibuprofen lysine injection (NeoProfen&reg;): I.V: For I.V. administration only; administration via umbilical arterial line has not been evaluated. Dilute with dextrose or saline to an appropriate volume. Infuse over 15 minutes through I.V. port closest to insertion site. Avoid extravasation. Do not administer simultaneously via same line with TPN. If needed, interrupt TPN for 15 minutes prior to and after ibuprofen administration, keeping line open with dextrose or saline.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibuprofen injection (Caldolor&reg;) I.V.: For I.V. administration only; must be diluted to a final concentration of &le;4 mg/mL prior to administration; infuse over at least 30 minutes",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F2985823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibuprofen injection (Caldolor&reg;): Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibuprofen lysine injection (NeoProfen&reg;): Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with TPN solution.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F4412228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Suspension: Store at controlled room temperature of 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: Store at controlled room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibuprofen injection (Caldolor&reg;): Store intact vials at room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Must be diluted prior to use. Dilute with D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, or LR to a final concentration &le;4 mg/mL. Diluted solutions are stable for 24 hours at room temperature and room lighting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibuprofen lysine injection (NeoProfen&reg;): Store at controlled room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light; store injection vials in carton until ready to use. Stable in I.V. dextrose or saline solutions. Following dilution, administer within 30 minutes of preparation. Discard unused portion of vial (vial does not contain preservative).",
"     <b>",
"      Incompatible",
"     </b>",
"     with TPN solution.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1053336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Treatment of inflammatory diseases and rheumatoid disorders including juvenile idiopathic arthritis (JIA) [FDA approved in pediatric patients (age not specified)], rheumatoid arthritis (FDA approved in adults), and osteoarthritis (FDA approved in adults); mild to moderate pain (FDA approved in ages &ge;6 months and adults); reduction of fever (FDA approved in ages &ge;6 months and adults); primary dysmenorrhea (FDA approved in adults); migraine pain; gout; cystic fibrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibuprofen injection (Caldolor&reg;):  Management of mild to moderate pain, management of moderate to severe pain when used concurrently with an opioid analgesic; reduction of fever (all indications FDA approved in ages &ge;17 years)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibuprofen lysine injection (NeoProfen&reg;): Treatment (ie, closure) of a clinically significant PDA when usual treatments are ineffective (FDA approved in premature neonates who weigh between 500-1500 g and who are &le;32 weeks gestational age).",
"     <b>",
"      Note:",
"     </b>",
"     The prophylactic use of ibuprofen is not currently indicated nor recommended (Ohlsson, 2009; Shah, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F181516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"       Haltran&reg; may be confused with Halfprin&reg;",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"       Motrin&reg; may be confused with Neurontin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Injectable formulations: Both ibuprofen and ibuprofen lysine are available for parenteral use. Ibuprofen lysine is",
"       <b>",
"        only",
"       </b>",
"       indicated for closure of a clinically-significant patent ductus arteriosus.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F181514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Oral:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Itching, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Fluid retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain/cramps/distress, appetite decreased, constipation, diarrhea, dyspepsia, epigastric pain, flatulence, heartburn, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute renal failure, agranulocytosis, anaphylaxis, aplastic anemia, azotemia, blurred vision, bone marrow suppression, confusion, creatinine clearance decreased, duodenal ulcer, edema, eosinophilia, epistaxis, erythema multiforme, gastric ulcer, GI bleed, GI hemorrhage, GI ulceration, hallucinations, hearing decreased, hematuria, hematocrit decreased, hemoglobin decreased, hemolytic anemia, hepatitis, hypertension, inhibition of platelet aggregation, jaundice, liver function tests abnormal, leukopenia, melena, neutropenia, pancreatitis, photosensitivity, Stevens-Johnson syndrome, thrombocytopenia, toxic amblyopia, toxic epidermal necrolysis, urticaria, vesiculobullous eruptions, vision changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Injection: Ibuprofen (Caldolor&reg;):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Edema, hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypernatremia, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, dyspepsia, flatulence, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hematologic: Anemia, hemorrhage, neutropenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Renal: BUN increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Cough",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Injection: Ibuprofen lysine (NeoProfen&reg;):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Edema, heart failure, intraventricular hemorrhage, hypotension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Skin irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Adrenal insufficiency, hypernatremia, hypocalcemia, hyper-/hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distension, feeding problems, gastritis, GI disorders, GI reflux, ileus, non NEC",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hematologic: Anemia,  neutropenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hepatic: Cholestasis, jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Local: Injection-site reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Apnea, respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Urea increased, renal impairment, creatinine increased, renal failure, urine output decreased (small decrease reported on days 2-6 with compensatory increase in output on day 9)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Respiratory failure, atelectasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Infection, inguinal hernia, sepsis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: GI perforation, necrotizing enterocolitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1053341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ibuprofen or any component; history of asthma, urticaria, or allergic-type reaction to aspirin, or other NSAIDs; patients with the &ldquo;aspirin triad&rdquo; [asthma, rhinitis (with or without nasal polyps), and aspirin intolerance] (fatal asthmatic and anaphylactoid reactions may occur in these patients); perioperative pain in the setting of coronary artery bypass graft (CABG)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Ibuprofen lysine injection (NeoProfen&reg;) is contraindicated in preterm neonates with untreated proven or suspected infection; congenital heart disease where patency of the PDA is necessary for pulmonary or systemic blood flow (eg, pulmonary atresia, severe tetralogy of Fallot, severe coarctation of aorta); bleeding (especially with active intracranial hemorrhage or GI bleed); thrombocytopenia; coagulation defects; proven or suspected necrotizing enterocolitis (NEC); significant renal dysfunction",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1053325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with decreased hepatic function; closely monitor patients with abnormal LFTs; severe hepatic reactions (eg, fulminant hepatitis, liver failure) have occurred with NSAID use, rarely; discontinue if signs or symptoms of liver disease develop, or if systemic manifestations occur. Use with caution in patients with asthma; asthmatic patients may have aspirin-sensitive asthma which may be associated with severe and potentially fatal bronchospasm when aspirin or NSAIDs are administered. Anemia (due to occult or gross blood loss from the GI tract, fluid retention, or other effect on erythropoiesis) may occur; monitor hemoglobin and hematocrit in patients receiving long-term therapy. Use with caution and monitor carefully in patients with coagulation disorders or those receiving anticoagulants; NSAIDs inhibit platelet aggregation and may prolong bleeding time. May increase the risk of aseptic meningitis, especially in patients with systemic lupus erythematosus (SLE) and related connective tissue disorders. May cause vision changes (blurred or diminished vision, changes in color vision, scotomata); discontinue ibuprofen if such effects occur and obtain ophthalmologic examination with central visual fields and color vision testing.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Ibuprofen injection (Caldolor&reg;): Additional precautions: Product must be diluted prior to administration; hemolysis can occur if not diluted. Patients must be well hydrated before administration (to reduce risk of adverse effects on the kidneys).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Ibuprofen lysine injection (NeoProfen&reg;): Avoid extravasation; I.V. solution may be irritating to tissues. Use with caution in neonates with controlled infection or those at risk for infection; ibuprofen may alter the usual signs of infection. May inhibit platelet aggregation; monitor for signs of bleeding. Use with caution in neonates when total bilirubin is elevated; ibuprofen may displace bilirubin from albumin-binding sites. Intraventricular hemorrhage has been reported; overall incidence: 29%; grade 3/4: 15%. Long-term evaluations of neurodevelopmental outcome, growth, or diseases associated with prematurity (eg, chronic lung disease, retinopathy of prematurity) following treatment have not been conducted.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     OTC labeling: Prior to self-medication, patients should contact healthcare provider if they have or had recurring stomach pain or upset, ulcers, bleeding problems, high blood pressure, heart or kidney disease, other serious medical problems, or are currently taking a diuretic, aspirin, anticoagulant, or steroid drug. Recommended dosages should not be exceeded, due to an increased risk of GI bleeding. Consuming &ge;3 alcoholic beverages/day or taking this medication longer than recommended may also increase the risk of GI bleeding. Stop use and consult a healthcare provider if symptoms do not improve within first 24 hours of use (children), symptoms get worse or newly appear (children and adults), fever lasts for &gt;3 days (children and adults), or pain lasts &gt;3 days (children) and &gt;10 days (adults). Do not give for &gt;10 days unless instructed by healthcare provider (children and adults). For children with severe or persistent sore throat or sore throat with symptoms such as high fever, headache, nausea, and vomiting, consult healthcare provider immediately; do not use for treatment of sore throat for &gt;2 days or use in children &lt;3 years of age with sore throat, unless directed by physician.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Chewable tablets contain phenylalanine which must be avoided (or used with caution) in patients with phenylketonuria.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1053324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including potentially fatal MI and stroke",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease; carefully evaluate cardiovascular risk profile prior to prescribing; use the lowest effective dose for the shortest duration of time, taking into consideration individual patient treatment goals; alternate therapies should be considered for patients at high risk. Use is contraindicated for treatment of perioperative pain in the setting of CABG surgery",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; an increased incidence of MI and stroke was found in patients receiving COX-2 selective NSAIDs for the treatment of pain within the first 10-14 days after CABG surgery. NSAIDs may cause fluid retention, edema, and new onset or worsening of pre-existing hypertension; use with caution in patients with hypertension, CHF, or fluid retention. Response to ACE inhibitors, thiazides, or loop diuretics may be impaired with concurrent use of NSAIDs. Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs, may interfere with aspirin&rsquo;s cardioprotective effect.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     NSAIDs may increase the risk of gastrointestinal irritation, ulceration, bleeding, and perforation",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . These events, which can be potentially fatal, may occur at any time during therapy, and without warning. Avoid the use of NSAIDs in patients with active GI bleeding or ulcer disease. Use NSAIDs with extreme caution in patients with a history of GI bleeding or ulcers (these patients have a 10-fold increased risk for developing a GI bleed). Use NSAIDs with caution in patients with other risk factors which may increase GI bleeding (eg, concurrent therapy with aspirin, anticoagulants, and/or corticosteroids, longer duration of NSAID use, smoking, use of alcohol, and poor general health). Use the lowest effective dose for the shortest duration of time, taking into consideration individual patient treatment goals; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     NSAIDs may compromise existing renal function. Renal toxicity may occur in patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors; use with caution in these patients; rehydrate patient before starting therapy; monitor renal function closely. NSAIDs are not recommended for use in patients with advanced renal disease. Long-term use of NSAIDs may cause renal papillary necrosis and other renal injury.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     In neonates, pulmonary hypertension has occurred following use; five cases reported; three following early (prophylactic) administration of tromethamine ibuprofen and two cases following L-lysine ibuprofen for treatment of PDA (Bellini, 2006; Gournay, 2002; Ohlsson, 2008).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Fatal asthmatic and anaphylactoid reactions may occur in patients with the &ldquo;aspirin triad&rdquo; who receive NSAIDs. NSAIDs may cause serious dermatologic adverse reactions including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Avoid use of NSAIDs in late pregnancy as they may cause premature closure of the ductus arteriosus.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Some products contain sodium benzoate; benzoate is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; avoid use of ibuprofen products containing benzyl alcohol or sodium benzoate in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F181500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (minor), CYP2C9 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F181425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Ibuprofen may decrease the serum concentration of Imatinib. Specifically, ibuprofen may decrease intracellular concentrations of imatinib, leading to decreased clinical response.  Management: Consider using an alternative to ibuprofen in patients who are being treated with imatinib.  Available evidence suggests other NSAIDs do not interact in a similar manner.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Ibuprofen. Specifically, concentrations of the S-(+)-ibuprofen enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1053344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food may decrease the rate but not the extent of oral absorption",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F181426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C/D &ge;30 weeks gestation (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7684272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in the initial animal reproduction studies; therefore, the manufacturer classifies ibuprofen as pregnancy category C (category D: &ge;30 weeks gestation). NSAID exposure during the first trimester is not strongly associated with congenital malformations; however, cardiovascular anomalies and cleft palate have been observed following NSAID exposure in some studies. The use of a NSAID close to conception may be associated with an increased risk of miscarriage. Nonteratogenic effects have been observed following NSAID administration during the third trimester including: Myocardial degenerative changes, prenatal constriction of the ductus arteriosus, fetal tricuspid regurgitation, failure of the ductus arteriosus to close postnatally; renal dysfunction or failure, oligohydramnios; gastrointestinal bleeding or perforation, increased risk of necrotizing enterocolitis; intracranial bleeding (including intraventricular hemorrhage), platelet dysfunction with resultant bleeding; pulmonary hypertension. Because they may cause premature closure of the ductus arteriosus, use of NSAIDs late in pregnancy should be avoided (use after 31 or 32 weeks gestation is not recommended by some clinicians). Product labeling for Caldolor&reg; specifically notes that use at &ge;30 weeks gestation should be avoided and therefore classifies ibuprofen as pregnancy category D at this time. The chronic use of NSAIDs in women of reproductive age may be associated with infertility that is reversible upon discontinuation of the medication. A registry is available for pregnant women exposed to autoimmune medications including ibuprofen. For additional information contact the Organization of Teratology Information Specialists, OTIS Autoimmune Diseases Study, at 877-311-8972.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1053331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, serum electrolytes, occult blood loss, liver enzymes; urine output, serum BUN, and creatinine in patients receiving I.V. ibuprofen, concurrent diuretics, those with decreased renal function, or in patients on chronic therapy. Monitor preterm neonates for signs of bleeding and infection; serum electrolytes, glucose, calcium and bilirubin; vital signs; monitor I.V. site for signs of extravasation. Patients receiving long-term therapy for JIA should receive periodic ophthalmological exams.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1053335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Plasma concentrations &gt;200 mcg/mL may be associated with severe toxicity; cystic fibrosis: therapeutic peak plasma concentration: 50-100 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1053323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits prostaglandin synthesis by decreasing the activity of the enzyme, cyclooxygenase, which results in decreased formation of prostaglandin precursors",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1053339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Fever reduction:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Onset of action (single oral dose 8 mg/kg):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants &le;1 year: Mean &plusmn; SD: 69 &plusmn; 22 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;6 years: 109 &plusmn; 64 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maximum effect: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duration: 6-8 hours (dose-related)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1053340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid (80%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Ibuprofen follows a 2-compartment open model",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     , apparent: Preterm neonates, GA: 22-31 weeks and PNA: &lt;1 day old (n=21): 62.1 &plusmn; 3.9 mL/kg (Aranda, 1997)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     , central compartment: Preterm neonates, GA: 28.7 &plusmn; 1.3 weeks (n=13):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PNA 3 days old: 0.244 &plusmn; 0.084 L/kg (n=13); subset of 9 patients with ductal closure: 0.247 &plusmn; 0.102 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PNA 5 days old: 0.171 &plusmn; 0.077 L/kg (n=13); subset of 9 patients with ductal closure: 0.147 &plusmn; 0.075 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     The V",
"     <sub>",
"      d",
"     </sub>",
"     of the central compartment was significantly decreased on day 5 of life versus day 3; the decrease was more pronounced in patients with ductal closure (Van Overmeire, 2001).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Febrile children &lt;11 years: 0.2 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 0.12 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 90% to 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Oxidized in the liver;",
"     <b>",
"      Note:",
"     </b>",
"     Ibuprofen is a racemic mixture of R and S isomers; the R isomer (thought to be inactive) is slowly and incompletely (&sim;60%) converted to the S isomer (active) in adults; the amount of conversion in children is not known, but it is thought to be similar to adults; a study in preterm neonates estimated the conversion to be 61% after prophylactic ibuprofen use and 86% after curative treatment (Gregoire, 2004).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alpha (distribution): I.V.: Preterm neonates: 1.04 &plusmn; 1.48 hours (Van Overmeire, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Preterm newborn, GA: 22-31 weeks and PNA: &lt;1 day old (n=21): Beta half-life: 30.5 &plusmn; 4.2 hours (Aranda, 1997)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Preterm neonates, GA: 28.7 &plusmn; 1.3 weeks (n=13): Beta half-life: (Van Overmeire, 2001):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PNA 3 days old: 43.1 &plusmn; 26.1 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PNA 5 days old: 26.8 &plusmn; 23.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Preterm neonates, GA 24-27.9 weeks (n=62): R-enantiomer: 10 hours; S-enantiomer: 25.5 hours (Gregoire, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 1-2 hours; children 3 months to 10 years: Mean: 1.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Tablets: 1-2 hours; suspension: Mean: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children with cystic fibrosis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Suspension (n=22): 0.74 &plusmn; 0.43 hours (median: 30 minutes)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chewable tablet (n=4): 1.5 &plusmn; 0.58 hours (median: 1.5 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Tablet (n=12): 1.33 &plusmn; 0.95 hours (median: 1 hour)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: &sim;1% excreted as unchanged drug and 14% as conjugated ibuprofen in urine; 45% to 80% eliminated in urine as metabolites; some biliary excretion",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1053330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"      see \"Ibuprofen: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID); NSAIDs may cause serious adverse reactions, especially with overuse; use exactly as directed; do not increase dose or frequency; do not take longer than 3 days for fever (adults and children), 10 days for pain (adults), or 3 days for pain (children) without consulting healthcare professional. NSAIDs may increase the risk for heart attack, stroke, or ulcers and bleeding in stomach or intestines; GI bleeding, ulceration, or perforation can occur with or without pain. Notify physician before use if you have hypertension, heart failure, heart or kidney disease, history of stomach ulcers or bleeding in stomach or intestines, or other medical problems. Read the patient Medication Guide that you receive with each prescription and refill of ibuprofen.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     While using this medication, do not use alcohol, excessive amounts of vitamin C, other prescription or OTC medications containing aspirin or salicylate, or other NSAIDs without consulting prescriber. Ibuprofen may cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. Notify physician if changes in vision occur, if pain worsens or lasts &gt;10 days in adults or &gt;3 days in children, if fever worsens or lasts &gt;3 days, if stomach pain or upset occurs, if swelling or redness occurs in painful area, or if any new symptoms appear. Stop taking medication and report ringing in ears; persistent cramping or stomach pain; unresolved nausea or vomiting; respiratory difficulty or shortness of breath; unusual bruising or bleeding (mouth, urine, stool); skin rash; unusual swelling of extremities; chest pain; or palpitations.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     OTC (pediatrics; also see above paragraphs): Notify physician if child's condition does not improve or if worsens within first 24 hours of use. Do not give for &gt;10 days unless instructed by healthcare provider. For children with severe or persistent sore throat or sore throat with symptoms such as high fever, headache, nausea, and vomiting, consult healthcare provider immediately; do not use for treatment of sore throat for &gt;2 days or use in children &lt;3 years of age with sore throat, unless directed by physician.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1053342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nystagmus, dizziness, drowsiness, seizures, vomiting, hypotension, irregular heartbeat, breathing difficulties, apnea, kidney failure, and coma have been reported with overdose. Motrin&reg; suspension contains sucrose 0.3 g/mL and 1.6 calories/mL. Due to its effects on platelet function, ibuprofen should be withheld for at least 4-6 half-lives prior to surgical or dental procedures.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note",
"     </b>",
"     : A study comparing the short-term use of acetaminophen and ibuprofen in 84,192 children (6 months to 12 years of age) found no significant difference in the rates of hospitalization for acute GI bleeding, acute renal failure, anaphylaxis or Reye's syndrome. (Four of 55,785 children in the ibuprofen group and zero of 28,130 children in the acetaminophen group were hospitalized with acute GI bleeding). A low WBC occurred more frequently in the ibuprofen group (8 vs 0) (Lesko, 1995). A subanalysis of 27,065 children &lt;2 years of age also found no significant difference in the rates of hospitalization. (Three of 17,938 children in the ibuprofen group and zero of 9,127 children in the acetaminophen group were hospitalized with GI bleeding) (Lesko, 1999).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     There is currently no scientific evidence to support alternating acetaminophen with ibuprofen in the treatment of fever (Mayoral, 2000)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     I.V. ibuprofen is as effective as I.V. indomethacin for the treatment of PDA in preterm neonates, but is less likely to cause adverse effects on renal function (eg, oliguria, increased serum creatinine) (Aranda, 2006; Lago, 2002; Ohlsson, 2010; Van Overmeire, 2000). Ibuprofen (compared to indomethacin) also has been shown to decrease the risk of developing NEC (Ohlsson, 2010). However, five cases of pulmonary hypertension in neonates receiving ibuprofen have been reported (Bellini, 2006; Gournay 2002; Ohlsson, 2010). Further studies, especially long-term studies, are needed.",
"     <b>",
"      Note:",
"     </b>",
"     Orogastric administration of ibuprofen for PDA closure may be as effective as I.V.; however, due to the potential increase of GI toxicities, the orogastric route is not currently recommended (Amoozgar, 2009; Capparelli, 2007; Cherif, 2008; Erdeve, 2009; Ohlsson, 2010).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Amoozgar H, Ghodstehrani M, and Pishva N, \"Oral Ibuprofen and Ductus Arteriosus Closure in Full-Term Neonates: A Prospective Case-Control Study,\"",
"      <i>",
"       Pediatr Cardiol",
"      </i>",
"      , 2009 [Epub ahead of print].",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7946/abstract-text/19841966/pubmed\" id=\"19841966\" target=\"_blank\">",
"        19841966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aranda JV and Thomas R, \"Systematic Review: Intravenous Ibuprofen in Preterm Newborns,\"",
"      <i>",
"       Semin Perinatol",
"      </i>",
"      , 2006, 30(3):114-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7946/abstract-text/16813969/pubmed\" id=\"16813969\" target=\"_blank\">",
"        16813969",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aranda JV, Varvarigou A, Beharry K, et al, \"Pharmacokinetics and Protein Binding of Intravenous Ibuprofen in the Premature Newborn Infant,\"",
"      <i>",
"       Acta Paediatr",
"      </i>",
"      , 1997, 86(3):289-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7946/abstract-text/9099319/pubmed\" id=\"9099319\" target=\"_blank\">",
"        9099319",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bellini C, Campone F, and Serra G, \"Pulmonary Hypertension Following L-lysine Ibuprofen Therapy in a Preterm Infant With Patent Ductus Arteriosus,\"",
"      <i>",
"       CMAJ",
"      </i>",
"      , 2006, 174(13):1843-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7946/abstract-text/16785458/pubmed\" id=\"16785458\" target=\"_blank\">",
"        16785458",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berde C, Ablin A, Glazer J, et al, &ldquo;American Academy of Pediatrics Report of the Subcommittee on Disease-Related Pain in Childhood Cancer,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1990, 86(5 Pt 2):818-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7946/abstract-text/2216644/pubmed\" id=\"2216644\" target=\"_blank\">",
"        2216644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Capone ML, Sciulli MG, Tacconelli S, et al. &ldquo;Pharmacodynamic Interaction of Naproxen With Low-Dose Aspirin in Healthy Subjects,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2005, 45(8):1295-1301.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7946/abstract-text/15837265/pubmed\" id=\"15837265\" target=\"_blank\">",
"        15837265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Capparelli EV, \"Pharmacologic, Pharmacodynamic, and Pharmacokinetic Considerations With Intravenous Ibuprofen Lysine,\"",
"      <i>",
"       J Pediatr Pharmacol Ther",
"      </i>",
"      , 2007, 12:158-70.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Catella-Lawson F, Reilly MP, Kapoor SC, et al. &ldquo;Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(25):1809-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7946/abstract-text/11752357/pubmed\" id=\"11752357\" target=\"_blank\">",
"        11752357",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cherif A, Khrouf N, Jabnoun S, et al, \"Randomized Pilot Study Comparing Oral Ibuprofen With Intravenous Ibuprofen in Very Low Birth Weight Infants With Patent Ductus Arteriosus,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 122(6):e1256-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7946/abstract-text/19047225/pubmed\" id=\"19047225\" target=\"_blank\">",
"        19047225",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cryer B, Berlin RG, Cooper SA, et al. &ldquo;Double-Blind, Randomized, Parallel, Placebo-Controlled Study Of Ibuprofen Effects On Thromboxane B2 Concentrations In Aspirin-Treated Healthy Adult Volunteers,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2005, 27(2):185-191.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7946/abstract-text/15811481/pubmed\" id=\"15811481\" target=\"_blank\">",
"        15811481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Erdeve O, Gokmen T, Altug N, et al, \"Oral Versus Intravenous Ibuprofen: Which Is Better in Closure of Patent Ductus Arteriosus?\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2009, 123(4):e763.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7946/abstract-text/19336363/pubmed\" id=\"19336363\" target=\"_blank\">",
"        19336363",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gal P, Ransom JL, and Davis SA, \"Possible Ibuprofen-Induced Kernicterus in a Near-Term Infant With Moderate Hyperbilirubinemia,\"",
"      <i>",
"       J Pediatr Pharmacol Ther",
"      </i>",
"      , 2006, 11:245-50.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gournay V, Savagner C, Thiriez G, et al, \"Pulmonary Hypertension After Ibuprofen Prophylaxis in Very Preterm Infants,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 359(9316):1486-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7946/abstract-text/11988250/pubmed\" id=\"11988250\" target=\"_blank\">",
"        11988250",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gregoire N, Gualano V, Geneteau A, et al, \"Population Pharmacokinetics of Ibuprofen Enantiomers in Very Premature Neonates,\"",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2004, 44(10):1114-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7946/abstract-text/15342612/pubmed\" id=\"15342612\" target=\"_blank\">",
"        15342612",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kauffman RE and Nelson MV, &ldquo;Effect of Age on Ibuprofen Pharmacokinetics and Antipyretic Response,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1992, 121(6):969-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7946/abstract-text/ 1447669 /pubmed\" id=\" 1447669 \" target=\"_blank\">",
"        1447669",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Konstan MW, Byard PJ, Hoppel CL, et al, &ldquo;Effect of High-Dose Ibuprofen in Patients With Cystic Fibrosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 332(13):848-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7946/abstract-text/7503838/pubmed\" id=\"7503838\" target=\"_blank\">",
"        7503838",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lago P, Bettiol T, Salvadori S, et al, \"Safety and Efficacy of Ibuprofen Versus Indomethacin in Preterm Infants Treated for Patent Ductus Arteriosus: A Randomised Controlled Trial,\"",
"      <i>",
"       Eur J Pediatr",
"      </i>",
"      , 2002, 161(4):202-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7946/abstract-text/12014386/pubmed\" id=\"12014386\" target=\"_blank\">",
"        12014386",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lesko SM and Mitchell AA, &ldquo;An Assessment of the Safety of Pediatric Ibuprofen. A Practitioner-Based Randomized Clinical Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1995, 273(12):929-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7946/abstract-text/7884951/pubmed\" id=\"7884951\" target=\"_blank\">",
"        7884951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lesko SM and Mitchell A, &ldquo;The Safety of Acetaminophen and Ibuprofen Among Children Younger Than Two Years Old,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1999, 104(4), file://www.pediatrics.org/cgi/content/full/104/4/e39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7946/abstract-text/10506264 /pubmed\" id=\"10506264 \" target=\"_blank\">",
"        10506264",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mayoral CE, Marino RV, Rosenfeld, W, et al, &ldquo;Alternating Antipyretics: Is This an Alternative?&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2000, 105(5):1009-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7946/abstract-text/10790455/pubmed\" id=\"10790455\" target=\"_blank\">",
"        10790455",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ohlsson A and Shah SS, \"Ibuprofen for the Prevention of Patent Ductus Arteriosus in Preterm and/or Low Birth Weight Infants (Review),\"",
"      <i>",
"       Cochrane Database Syst Rev",
"      </i>",
"      , 2009, 3.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ohlsson A, Walia R, and Shah S, \"Ibuprofen for the Treatment of Patent Ductus Arteriosus in Preterm and/or Low Birth Weight Infants,\"",
"      <i>",
"       Cochrane Database Syst Rev",
"      </i>",
"      , 2010, (4):CD003481.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7946/abstract-text/18254020/pubmed\" id=\"18254020\" target=\"_blank\">",
"        18254020",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pai VB, Sakadjian A, and Puthoff TD, \"Ibuprofen Lysine for the Prevention and Treatment of Patent Ductus Arteriosus,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2008, 28(9):1162-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7946/abstract-text/18752387/pubmed\" id=\"18752387\" target=\"_blank\">",
"        18752387",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scott CS, Retsch-Bogart GZ, Kustra RP, et al, &ldquo;The Pharmacokinetics of Ibuprofen Suspension, Chewable Tablets, and Tablets in Children With Cystic Fibrosis,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1999, 134(1):58-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7946/abstract-text/9880450/pubmed\" id=\"9880450\" target=\"_blank\">",
"        9880450",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Overmeire B, \"Common Clinical and Practical Questions on the Use of Intravenous Ibuprofen Lysine for the Treatment of Patent Ductus Arteriosus,\"",
"      <i>",
"       J Pediatr Pharmacol Ther",
"      </i>",
"      , 2007, 12:194-206.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Overmeire B, Smets K, Lecoutere D, et al, &ldquo;A Comparison of Ibuprofen and Indomethacin for Closure of Patent Ductus Arteriosus,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 343(10):674-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7946/abstract-text/10974130/pubmed\" id=\"10974130\" target=\"_blank\">",
"        10974130",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Overmeire B, Touw D, Schepens PJ, et al, \"Ibuprofen Pharmacokinetics in Preterm Infants With Patent Ductus Arteriosus,\" Clin Pharmacol Ther, 2001, 70(4):336-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/48/7946/abstract-text/11673749/pubmed\" id=\"11673749\" target=\"_blank\">",
"        11673749",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13371 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-8DAC4F1F78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_48_7946=[""].join("\n");
var outline_f7_48_7946=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708913\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181456\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181457\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053332\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442611\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053326\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181430\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181416\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874617\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053337\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2985823\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4412228\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053336\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181516\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181514\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053341\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053325\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053324\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181500\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181425\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053344\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181426\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7684272\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053331\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053335\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053323\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053339\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053340\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053330\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053342\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13371\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13371|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=related_link\">",
"      Ibuprofen: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=related_link\">",
"      Ibuprofen: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_48_7947="Diseases associated with HTLV-1 infection";
var content_f7_48_7947=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66919&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66919&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diseases associated with HTLV-1 infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Major",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adult T-cell leukemia/lymphoma (ATLL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HTLV-I-associated myelopathy (HAM)/tropical spastic paraparesis (TSP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Minor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infective dermatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uveitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arthropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sjogren's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Raynaud syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polymyositis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary lymphocytic alveolitis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_48_7947=[""].join("\n");
var outline_f7_48_7947=null;
var title_f7_48_7948="Abdominal hyst complication";
var content_f7_48_7948=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Complications of abdominal hysterectomy for benign disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rate of complications, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Overall severe complications",
"       </td>",
"       <td>",
"        4* to 6&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Major hemorrhage (requiring transfusion or surgical intervention)",
"       </td>",
"       <td>",
"        2*&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thromboembolism",
"       </td>",
"       <td>",
"        0.2 (with mechanical or pharmacologic thromboprophylaxis)&Delta;; 15 to 30 (without thromboprophylaxis)&loz;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bladder injury",
"       </td>",
"       <td>",
"        0.02&sect; to 1&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ureteral injury",
"       </td>",
"       <td>",
"        0.04&sect;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinary tract infection",
"       </td>",
"       <td>",
"        4&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bowel injury",
"       </td>",
"       <td>",
"        0.2&Delta; to 1&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bowel obstruction",
"       </td>",
"       <td>",
"        1&yen;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Surgical site infection",
"       </td>",
"       <td>",
"        3&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reoperation",
"       </td>",
"       <td>",
"        0.5*&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mortality",
"       </td>",
"       <td>",
"        0.03*",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Maresh MJ, Metcalfe MA, McPherson K, et al. BJOG 2002; 109:302.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      Garry R, Fountain J, Mason S, et al. BMJ 2004; 328:129.",
"      <br>",
"       &Delta; Makinen J, Johansson J, Tomas C, et al. Hum Reprod 2001; 16:1473.",
"       <br>",
"        <font class=\"lozenge\">",
"         &loz;",
"        </font>",
"        Greer IA. Baillieres Clin Obstet Gynaecol 1997; 11:403.",
"        <br>",
"         &sect; Harkki-Siren P, Sjoberg J, Tiitinen A. Obstet Gynecol 1998; 92:113.",
"         <br>",
"          &yen; Al-Sunaidi M, Tulandi T. Obstet Gynecol 2006; 108:1162.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_48_7948=[""].join("\n");
var outline_f7_48_7948=null;
var title_f7_48_7949="Fiber content of food";
var content_f7_48_7949=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60358&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60358&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Fiber content of foods",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Food",
"       </td>",
"       <td class=\"subtitle1\">",
"        Average fiber per serving, g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Vegetables",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Beans (navy, lima, kidney, baked)",
"       </td>",
"       <td>",
"        8.5 to 10.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Beans (string)",
"       </td>",
"       <td>",
"        2.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Broccoli",
"       </td>",
"       <td>",
"        3.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Brussels sprouts",
"       </td>",
"       <td>",
"        2.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cabbage",
"       </td>",
"       <td>",
"        2.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Carrots",
"       </td>",
"       <td>",
"        2.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Celery",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Corn",
"       </td>",
"       <td>",
"        2.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Corn on the cob",
"       </td>",
"       <td>",
"        5.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lettuce",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Potato (baked with skin)",
"       </td>",
"       <td>",
"        3.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Potato (french fries)",
"       </td>",
"       <td>",
"        1.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Peas (canned)",
"       </td>",
"       <td>",
"        6.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rice",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Fruit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Apple with peel",
"       </td>",
"       <td>",
"        2.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Apple juice",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Banana",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Grapefruit (fresh)",
"       </td>",
"       <td>",
"        0.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Orange",
"       </td>",
"       <td>",
"        2.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Peach",
"       </td>",
"       <td>",
"        2.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Raspberries",
"       </td>",
"       <td>",
"        4.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Strawberries",
"       </td>",
"       <td>",
"        1.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Bread",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Whole wheat",
"       </td>",
"       <td>",
"        1.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        White, rye, French",
"       </td>",
"       <td>",
"        0.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Cereal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        All bran (100 percent)",
"       </td>",
"       <td>",
"        8.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Corn flakes",
"       </td>",
"       <td>",
"        2.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Wheaties",
"       </td>",
"       <td>",
"        2.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Meats (chicken, liver, fish, lamb)",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cheese, milk, yogurt",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Cheskin, LJ, Principles of Ambulatory Medicine, 4th ed, Williams &amp; Wilkins, Baltimore, 1995, p. 479.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_48_7949=[""].join("\n");
var outline_f7_48_7949=null;
var title_f7_48_7950="HCT-CI and CCI";
var content_f7_48_7950=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F59272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F59272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of Charlson Comorbidity Index (CCI) and Hematopoietic cell transplantation-specific comorbidity index (HCT-CI) scoring systems",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Comorbidity",
"       </td>",
"       <td class=\"subtitle1\">",
"        CCI definition",
"       </td>",
"       <td class=\"subtitle1\">",
"        CCI score",
"       </td>",
"       <td class=\"subtitle1\">",
"        HCT-CI definition",
"       </td>",
"       <td class=\"subtitle1\">",
"        HCT-CI score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Pulmonary disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mild",
"       </td>",
"       <td>",
"        Dyspnea on moderate activity (or with asthma attacks)",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Dyspnea on moderate activity or DLco and/or FEV",
"        <sub>",
"         1",
"        </sub>",
"        81 to 90 percent",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Moderate",
"       </td>",
"       <td>",
"        Dyspnea on slight activity",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Dyspnea on slight activity or DLco and/or FEV",
"        <sub>",
"         1",
"        </sub>",
"        66 to 80 percent",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Severe",
"       </td>",
"       <td>",
"        Dyspnea at rest or requires oxygen",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Dyspnea at rest or requires oxygen or DLco and/or FEV",
"        <sub>",
"         1",
"        </sub>",
"        &le;65 percent",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Cardiac disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        General",
"       </td>",
"       <td>",
"        Congestive heart failure (symptomatic and requiring treatment) and myocardial infarction were included as independent comorbidities, each acquiring a score of 1",
"       </td>",
"       <td>",
"        1 or 2",
"       </td>",
"       <td>",
"        Coronary artery disease*, congestive heart failure, myocardial infarction, or EF &le;50 percent",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Arrhythmia",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Heart valve disease",
"       </td>",
"       <td>",
"        Except mitral valve prolapse",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Except mitral valve prolapse",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Hepatic disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mild",
"       </td>",
"       <td>",
"        Chronic hepatitis or cirrhosis",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Chronic hepatitis, bilirubin &gt;ULN to 1.5 X ULN, or AST/ALT &gt;ULN to 2.5 X ULN",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Moderate to severe",
"       </td>",
"       <td>",
"        Cirrhosis with portal hypertension &plusmn; bleeding varices",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        Cirrhosis or fibrosis or bilirubin &gt;1.5 X ULN or AST/ALT &gt;2.5 X ULN",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Renal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mild",
"       </td>",
"       <td>",
"        Serum creatinine 2 to 3 mg/dL",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Creatinine 1.2 to 2 mg/dL",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Moderate to severe",
"       </td>",
"       <td>",
"        Creatinine &gt;3 mg/dL, renal dialysis, or renal transplant",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        Creatinine &gt;2 mg/dL, renal dialysis, or renal transplant",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Other malignancies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prior solid tumor",
"       </td>",
"       <td>",
"        Initially treated in the last five years",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        Treated at any time point in the patient's past history, excluding nonmelanoma skin cancer",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Metastatic cancer",
"       </td>",
"       <td>",
"        Present",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        Not included",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Other comorbidities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diabetes",
"       </td>",
"       <td>",
"        Requiring treatment with insulin or oral hypoglycemics but not diet alone",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Requiring treatment with insulin or oral hypoglycemics but not diet alone",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cerebrovascular disease",
"       </td>",
"       <td>",
"        Transient ischemic attack or cerebrovascular accident",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Transient ischemic attack or cerebrovascular accident",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rheumatologic",
"       </td>",
"       <td>",
"        SLE, RA, polymyositis, mixed CTD, or polymyalgia rheumatica",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        SLE, RA, polymyositis, mixed CTD, or polymyalgia rheumatica",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Peptic ulcer",
"       </td>",
"       <td>",
"        Requiring treatment",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Requiring treatment",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Psychiatric disturbance",
"       </td>",
"       <td>",
"        Not included",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        Depression or anxiety requiring psychiatric consult or treatment",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Infection",
"       </td>",
"       <td>",
"        Not included",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        Requiring continuation of antimicrobial treatment after day 0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inflammatory bowel disease",
"       </td>",
"       <td>",
"        Not included",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        Crohn disease or ulcerative colitis",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Obesity",
"       </td>",
"       <td>",
"        Not included",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        Patients with a body mass index &gt;35 kg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    To convert creatinine from milligrams per deciliter to micromoles per liter, multiply milligrams per deciliter by 88.4.",
"    <div class=\"footnotes\">",
"     DLco: diffusion capacity of carbon monoxide; FEV",
"     <sub>",
"      1",
"     </sub>",
"     : forced expiratory volume in one second; EF: ejection fraction; ULN: upper limit of normal; AST: aspartate aminotransferase; ALT: alanine aminotransferase; SLE: systemic lupus erythematosis; RA: rheumatoid arthritis; CTD: connective tissue disease.",
"     <br/>",
"     * One or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106:2912.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_48_7950=[""].join("\n");
var outline_f7_48_7950=null;
var title_f7_48_7951="Pleural fluid output after lung transplantation";
var content_f7_48_7951=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Course of pleural fluid after lung transplantation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 301px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Daily pleural fluid output in six consecutive single lung transplant recipients. Patient 4 developed&nbsp;primary lung&nbsp;graft dysfunction&nbsp;and was reintubated on the second postoperative day. His pulmonary edema rapidly cleared in parallel with a reduction in daily pleural fluid output. He was extubated on day four.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_48_7951=[""].join("\n");
var outline_f7_48_7951=null;
